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Drug use is a major burden in Cape Town, South Africa, and at times may be fatal. Individuals 
suspected to have demised from drug intoxication are referred for medico-legal investigation, 
in order for cause of death to be determined. Sometimes, it remains ambiguous as to whether 
the drug intoxication was suicidal or accidental, even after a full post-mortem examination. 
Literature has shown that molecular analysis of genetic variants in genes encoding for drug 
metabolising enzymes may provide insight into the manner of death. At Cape Town’s Salt 
River Mortuary, numerous toxicological-related cases yield ambiguous results, which may 
potentially be resolved with molecular analyses. However, no optimised molecular assay to 
sequence drug metabolising enzymes currently exists in a local context. The aim of this project 
was to design and optimise a molecular-based assay to sequence the drug metabolising enzyme, 
CYP2D6. Subsequent to primer design, exons in CYP2D6 were amplified and sequenced. The 
optimised assay was then applied to DNA from two decedents suspected to have demised from 
drug intoxication. Following a toxicological drug screen, certain drugs metabolised by 
CYP2D6 were reported. The assay revealed genetic variants within CYP2D6; both individuals 
were heterozygous for 138insT, rendering one allele in each individual defective. While one 
decedent also exhibited variants with normal and unknown haplotypes, the other decedent was 
homozygous for *17 (decreased functionality), overall making the former an intermediate 
(altered) or extensive (normal) metaboliser and the latter, an intermediate metaboliser of 
specific drugs. Quantitative toxicological results were unavailable; consequently, the 
contribution of the metabolism phenotype on death in these cases could not be established. 
However, the genetic variants, combined with the presence of these drugs in each case, 
suggests altered drug metabolism, which should be investigated further and interpreted within 
each case context. These findings would also be beneficial to the decedents’ living relatives, 
who may also carry these variants. Overall, this study demonstrates the value of molecular 
analyses in forensic investigations of toxicological-related fatalities, and lays the foundation 
for additional future research, particularly since the molecular assay has now been successfully 
optimised.   
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1. Introduction 
 




To date, literature reviews have not collated information on the variations of the CYP2D6 gene 
from a forensic post-mortem perspective for indigenous Black African populations. Given the 
diversity observed in indigenous Black African populations and the importance of identifying 
the association between drug-metabolising enzymes and forensic post-mortem cases, it is 
important to review the literature and collate what is already known about identified CYP2D6 
variants in order to reveal the gaps requiring further study (Gaedigk and Coetsee, 2008). 
Pharmacogenetics, is the study of genetic polymorphisms in drug-metabolising enzymes and 
is a science that has been thoroughly explored globally. One of the most highly polymorphic 
and studied of these drug-metabolising enzymes is CYP2D6 (Alessandrini et al., 2013). Many 
studies have investigated the CYP2D6 variants associated with adverse drug reactions (ADRs). 
When compared globally, however, there have been relatively few studies performed on 
indigenous Black African populations (Alessandrini et al., 2013).  
Toxicogenetics has derived from pharmacogenetics and is defined as the study of genetic 
variations that cause variable drug responses through polymorphisms of drug transporters, drug 
metabolising enzymes and drug receptors (Severino and Del Zompo, 2004). It focuses on how 
variations are manifested, how they interact to produce specific phenotypes and how these 
phenotypes affect drug response (Severino and Del Zompo, 2004). This discipline is not yet 
fully utilised in the South African Forensic Medicine context.  
South Africa has witnessed an exponential growth of drug abuse to epidemic proportions – 
widely attributed to the relatively cheap costs and increased availability – which may have 
contributed to an increase in toxicological-related deaths (Dada et al., 2015). Using 
toxicological analyses to determine the manner of death (MoD) in such instances, is not always 
straightforward. In ambiguous cases, for instance when high concentrations of drugs are 
present in the blood, despite therapeutic doses, or when metabolites are present in biological 
specimens in a manner inconsistent with prescription history or reported consumption, the 
MoD remains ‘undetermined’. Since these ambiguous cases are often not resolved by current 
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analytical practices, expanding post-mortem investigations to include a genetic component, 
‘Molecular Autopsies’, is being explored (Sajantila et al., 2010). 
The limited knowledge of polymorphisms and their impact in indigenous Black African 
populations may underestimate the importance of their forensic application in toxicogenetics 
(Matimba et al., 2009).  
1.1.2 Substance Use and Abuse 
 
Widespread concern regarding the rise in substance use and abuse has given rise to a global 
‘war on drugs’. It was estimated that around 250 million people (5% of the world’s population) 
used an illicit drug at least once in 2015 (UNODC, 2017). Most countries have experienced an 
exponential increase in drug use and this has been witnessed, particularly, amongst the youth 
(Crouch and Wegner, 2014). Developing countries, in particular, are vulnerable to the increase 
in drug use, which places pressure on their health systems, society and economy (Crouch and 
Wegner, 2014). Factors including informal settlements, poverty, crime, unemployment, drug-
dependent social groups and social uncertainty create a fecund environment for substance 
abuse (James, 1999). Drugs are popularly used and abused, which has been reported to 
fabricate an entire drug culture, particularly amongst the impoverished (Newcomb and Bentler, 
1989; Abadinsky, 2017).  
Recreational substance use is defined as the general use of any psychoactive substance that 
usually starts on an experimental basis (Brook et al., 2006). In some instances, experimentation 
leads to substance abuse, which is defined as the routine use of a substance, consumed in excess 
of the therapeutic amount or with methods that are dangerous to themselves or others (Orwa, 
2014; Crouch and Wegner, 2014). Substances of abuse are often categorised according to the 
drug’s medical use and dependency potential (US Department of Justice, United States Drug 
Enforcement Administration, 2013). In South Africa, the primary consideration in classifying 
a drug, according to the Medicines Control Council, is the drug’s safety profile regarding the 
therapeutic indications for its use. Drugs are listed into schedules based on route of 
administration, strength, dose, duration of treatment or a combination of these factors 
(Medicines Control Council, 2014). 
Although the emphasis of substance abuse normally pertains to illicit drugs, over-the-counter 
and prescription medication (therapeutic drugs) are also abused (Crouch and Wegner, 2014). 
Commonly abused illicit drugs include substances in the cannabis, opioid, cocaine or 
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amphetamine-type stimulant groups, while commonly abused prescription medications include 
opioid analgesics, stimulants and sedative hypnotics (Orwa, 2014). The substances abused are 
often a result of what is commonly available, which may depend on the socio-economic status 
of the individual or the community. Some of these substances are produced within the borders 
of a country, while many others are shipped in from other parts of the world. According to the 
United Nations Office on Drugs and Crime (UNODC), South Africa features as an international 
transit country and regional hub for illicit drugs entering Southern Africa (Orwa, 2014).  
1.1.3 Commonly Abused Substances in the Western Cape 
 
As observed globally, drug abuse in the Western Cape is ever increasing and the pattern of 
commonly used drugs is constantly changing (Odejide, 2006). Currently, uncontrolled 
substance abuse in the Western Cape is adversely affecting not only adults and adolescents but 
the youth as well (Odejide, 2006).  
The most commonly abused psychoactive substances in the Western Cape include alcohol, 
cannabis, methamphetamine and methaqualone (Parry et al., 2004; Dada et al., 2015). 
Methaqualone, commonly known by its trade name Mandrax, was previously – from data 
collected in a study by Parry et al. (2004) – the second most frequently reported substance of 
abuse, after cannabis, in adolescents in Cape Town between 1997 and 2001. Mandrax is a 
sedative and hypnotic drug which is often mixed with cannabis, as it is said to enhance the 
psychoactive effects of the active ingredient in cannabis, Δ9- tetrahydrocannabinol (THC) (da 
Silva et al., 2007). Mandrax is known to have highly addictive properties, producing both 
physical and psychological dependence (da Silva et al., 2007). 
Since 2005, the Cape Town area has seen a sudden increase in the level of abuse of 
methamphetamine hydrochloride, which is believed to be smuggled in from China (Odejide, 
2006; Orwa, 2014). Methamphetamine – with its numerous forms and street names – is easily 
administered through smoking or intravenous injection and is a powerful addictive stimulant 
that produces heightened energy levels, alertness, hyper-sexuality and an intense euphoric 
sensation (Orwa, 2014; Panenka et al., 2013; Meade et al., 2015). The bitter white powder can 
be manufactured locally from commonly available household reagents. Methamphetamine 
abuse in the Western Cape has grown to epidemic proportions, widely attributed to the 
relatively cheap costs and increased availability (Dada et al., 2015). Between 2005 and 2009, 
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methamphetamine was documented as the primary drug of abuse in the Western Cape, having 
overtaken Mandrax and cannabis (van Heerden et al., 2009).  
Historically, substance abuse data in South Africa has been limited and has largely been 
derived from rehabilitation centres (Dada et al., 2016). This information, although not an ideal 
representation, does highlight worrisome statistics. Given the lack of accessibility to 
intervention by much of the population, it has become a crisis in which death may often be the 
consequence (Crouch and Wegner, 2014). 
1.1.4 Medico-Legal Forensic Investigations 
 
In South Africa, the provincial Department of Health’s Forensic Pathology Service performs 
medico-legal investigations of deaths, which were or may have resulted from unnatural causes 
(Vincent et al., 2015). These examinations are conducted primarily in terms of the Inquest Act 
(Act no. 58 of 1959) and may only be performed by authorised medical practitioners (primarily 
Forensic Pathologists) (du Toit-Prinsloo and Saayman, 2012). Since, these medico-legal 
examinations are mandated by law, they can be performed without the consent of the next-of-
kin (du Toit-Prinsloo and Saayman, 2012). These investigations include the examination of a 
body with the purpose of establishing the cause of death (CoD) and/or circumstances 
surrounding the death (National Health Act, Act no. 61 of 2003). 
The National Health Act (Act no. 61 of 2003), regards the following to be deaths from 
unnatural causes: (i) “any death due to physical or chemical, direct or indirect, and/or related 
complications”; (ii) “any death, which in the opinion of the medical practitioner, has resulted 
from an act of omission or commission, which may be illegal/criminal in nature”; (iii) “any 
death as outlined in the Health Professions Amendment Act (Act no. 29 of  2007)”; and (iv) 
any death that is sudden and unexpected, or unexplained” (National Health Act, Act no. 61 of 
2003).  
Salt River Mortuary (SRM) and academic centre is a medico-legal facility that serves the West 
Metropole of the City of Cape Town and investigates more than 3500 cases per annum (M6 
graded). Due to the high case load, additional ancillary investigations which are not crucial to 
the determination of CoD cannot be supported in this resource-limited setting. In cases where 
the death is thought to be due to substance use or abuse, a medico-legal investigation is 
performed (National Health Act, Act no. 61 of 2003), which includes a comprehensive 
toxicological analysis. However, in cases involving violence, whereby the CoD is clear (e.g. 
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gunshot) then ancillary toxicological investigations are not performed in this setting, even 
though the use of drugs may contribute towards circumstances surrounding death.  
According to the Scientific Working Group for Forensic Toxicology (SWGTOX), forensic 
toxicology is the study of the adverse effects of drugs and chemicals on biological systems, 
whereby the adverse effects have administrative or medico-legal consequences (Forensic 
Toxicology Council, 2010). Toxicological-related cases require further investigation with 
forensic pathologists and toxicologists needing to establish the role of the substance in the 
causation of, or contribution to, death. Interpretation of forensic toxicological results is a task 
requiring knowledge of several aspects of pharmacology and analytical toxicology (Musshoff 
et al., 2010). In addition, post-mortem toxicology carries with it inherent challenges associated 
with analysis and interpretation in a deceased individual. For example, a number of drugs are 
unstable in a post-mortem environment and require careful consideration when interpreting 
their significance (Drummer, 2004). Drugs are also prone to degradation and redistributive 
processes, which may significantly alter their concentration (Drummer, 2004). These 
processes, together with individual factors such as the development of tolerance for a drug or 
genetic alteration in drug disposition, indicate that toxicological results should not be 
interpreted in isolation and a thorough investigation of the relevant circumstances is needed 
before a definitive conclusion of the possible effect of the substance on the body can be made 
(Drummer, 2004).  
One of the more common applications of post-mortem toxicology is the determination and 
interpretation of drug concentrations in the body, which is important in establishing the role of 
the drug in death in specific cases (Drummer, 2007). These concentrations may lie within 
therapeutic, toxic or ‘lethal’ levels. The term ‘therapeutic’ implies a concentration wherein the 
drug is expected to be effective without causing any toxic effects (Schulz et al., 2012). 
Conversely, ‘lethal’ concentrations are often suggested to contribute to death; however, these 
are largely based on reported fatal case studies. It is imperative that given individual and drug 
factors that alter the nature and extent of inter-individual toxicity, post-mortem toxicology 
should be interpreted in light of scene, medical and social history as well as autopsy and other 
investigative findings. While there have been substantial improvements in the understanding 
of the significance and application of forensic toxicology over the last 20 years, forensic 
pathologists and toxicologists are still faced with ambiguous cases in which toxicological 
results are either inconsistent with death or do not correspond to prescription or drug use history 
(Drummer, 2007). The challenges associated with the interpretation of post-mortem 
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toxicological results require consideration and strong understanding so as to apply to such 
ambiguous cases.  
1.1.5 Ambiguous Toxicity Cases 
 
Inconsistencies in post-mortem toxicology may include cases where high concentrations of 
drugs or metabolites, despite therapeutic doses, are found or vice versa; or if the concentrations 
do not appear to correlate to prescription medication history. This is often simply flagged as a 
reduced or increased functioning of the drug. The difficulty of interpreting such cases 
intensifies when there are no witnesses to the circumstances that may have led to the death or 
knowledge of the medical history and where there are inconsistencies with the amount of 
prescription medication on scene, particularly, when there is a suspected suicide but a history 
of suicide attempts is unknown (Sajantila et al., 2010).  
Literature indicates, in some of these cases, that genetic testing may be of value. In 
pharmacogenetic studies of neonatal opioid toxicity following maternal use of codeine during 
breastfeeding, there have been several reported cases of neonate deaths as a result of morphine 
toxicity from breastfeeding mothers that had consumed codeine prescribed for obstetric pain 
(Madadi et al., 2009). The cause was based on the mothers being CYP2D6 ultra-rapid 
metabolisers and not attributable to negligent use of medication. This genetic predisposition 
resulted in the prodrug codeine producing excessive morphine concentrations, which may 
distribute into milk, resulting in toxicity in the breastfed neonates (Madadi et al., 2009).  
Another study, by Sallee et al. (2000), reported that a 9-year-old boy, previously diagnosed 
with attention-deficit hyperactivity disorder, obsessive-compulsive disorder and Tourette’s 
Syndrome, died as a result of fluoxetine toxicity. Fluoxetine had been used to treat the child. It 
was found that a genetic predisposition of the CYP2D6 gene impairing the metabolism of the 
drug was responsible for high concentrations of fluoxetine in the blood and not excess 
administration of the drug (Sallee et al., 2000). Similarly, in a study by Jin et al. (2005) 
discussing 25 fentanyl toxicity cases, it was reported that 24 of the individuals died as a result 
of fentanyl toxicity whereby the manner of death was deemed accidental in 18 cases. The 
fentanyl toxicity was as a result of lowered enzyme activity of the CYP3A4 and 3A5 genes (Jin 
et al., 2005).   
These cases represent the necessity of ancillary investigations in determining CoD in cases 
where toxicology may be ambiguous. Although these ambiguous cases are often not resolved 
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by current post-mortem practices, expanding post-mortem investigations to include a genetic 
analysis as a component is one avenue that is currently being explored (Sajantila et al., 2010).  
1.1.6 Molecular Autopsies  
 
Interpretation of post-mortem toxicology in cases resulting from drug abuse or toxicity is 
complex. Distinguishing chronic from acute use of drugs may be complicated by time- and 
site-dependent variations in parent or metabolite concentrations as well as variation in 
metabolising phenotypes (Musshoff et al., 2010). Factors that affect an individual’s 
pathophysiological phenotype, as related to drug efficacy, may include physiological or, 
environmental factors, developmental age and, more importantly to this review, genetic 
variations (Sajantila et al., 2010; Agrawal and Rennert, 2012). The term ‘Molecular Autopsy’ 
is defined as the medico-legal investigation involving genetic testing and includes genotyping 
individuals to identify genetic predispositions and contributory factors towards death (Sajantila 
et al., 2010).  
An individual’s genetic makeup plays a pivotal role in the metabolism of drugs and often a 
reduced metabolic capacity, causing accidental toxicity, is a result of genetic variation (Kupiec 
et al., 2006; Neukamm et al., 2013). ADRs, is one of the leading causes of death in drug-related 
cases in the United States and is associated with abnormal pharmacokinetics (Jin et al., 2005; 
Andersen et al., 2013). ADRs not only result from abnormal pharmacokinetics, whereby 
genetic influences alter drug metabolism; but also, when there are synergistic effects between 
two or more drugs. ADR-related cases may benefit from the incorporation of molecular 
autopsies, and concerns regarding the underutilisation of this ancillary investigation, have been 
raised by the U.S. National Academy of Sciences (Sajantila et al., 2010). This sentiment should 
be in accordance with the development of the application of toxicogenetics in South Africa, 
where ADRs in a clinical setting have been reported to occur in 14% of hospitalised patients 
and result in a five to ten times higher fatality rate (Warnich et al., 2011). 
The value of molecular autopsies for unresolved ambiguous cases is threefold: firstly, genetic 
analyses have shown to resolve the CoD in numerous cases, which not only brings closure to 
the family of the deceased, but also enables improved targeting of public health resources 
(Nsubuga et al., 2006); secondly, the mechanisms underlying these deaths can be better 
understood, furthering research on preventative measures (Axler-DiPerte et al., 2014); and 
thirdly, genetic information on the risks for sudden unexpected, unexplained deaths or for 
adverse drug reactions fatal can be of paramount importance to living relatives who may be at 
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risk of  carrying the same genetic mutation (Axler-DiPerte et al., 2014). For these reasons, the 
aim of a study by Sanchez et al. (2016) was to evaluate whether molecular autopsies could 
increase the identification of the potential aetiology of death. Knowing the aetiology would be 
an ideal preventative measure that could identify which next-of-kin of the decedent should 
undergo further clinical genetic evaluation (Semsarian and Hamilton, 2012; Sanchez et al., 
2016). 
A 2008 study by Carturan et al. illustrated how up to 35% of cases sent for post-mortem genetic 
testing provided informative results, even though post-mortem samples were not collected in a 
‘DNA-friendly’ manner (according to protocols/guidelines), (Carturan et al., 2008). Molecular 
autopsies may decrease the amount of unresolved, undetermined and/or ambiguous cases, and 
may also provide a significant amount of genetic information about individual cases.  
1.1.7 The Role of CYP2D6 in Drug Metabolic Pathways 
 
The human body has the ability to carry out various chemical reactions using numerous 
mechanisms as a response to internal stimuli. These internal stimuli can result from the 
introduction of xenobiotics, such as drugs or toxins, into the body (Motulsky, 1957). The routes 
by which these drugs are metabolised or bio-transformed are countless and often vary among 
drug types. Metabolism of these xenobiotics occurs predominantly in the liver in two phases 
(Gibson and Skett, 1994). Phase I and phase II – of which the latter is often known to occur as 
a result of phase I metabolism (Gibson and Skett, 1994). Phase I metabolism, utilises enzymes 
such as Cytochrome P450 (CYP) enzymes, which catalyse more than 90% of the metabolic 
processes that occur in the liver, intestines and kidney while Phase II involves conjugation of 
drugs to improve their excretion (Arici and Ozhan, 2016; Tracy et al., 2016). This family of 
enzymes is responsible for the metabolism of many therapeutic and abused drugs, carcinogens 
and other endogenous substrates (Alessandrini et al., 2013). 
Cytochrome is derived from the haemoprotein nature of the enzyme, while “P450” is derived 
from the maximum wavelength at which the complex absorbs light (450 nm) (Jaiswal et al., 
1985). CYP450s are conveniently arranged into families and subfamilies, based on percent 
amino acid sequence identity. Enzymes sharing greater than or equal to 40 percent identity are 
assigned to a particular family, whereas those sharing greater than or equal to 55 percent 
identity make up a particular subfamily designated by a letter (Nelson, 2004). There are 57 
putatively functional human CYP450s, of which only a small subset within the CYP 1, 2, and 
3 families metabolise xenobiotics of interest to forensic toxicologists (Zanger & Schwab, 
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2013). The expression of these CYP450s are influenced by factors such as polymorphisms, 
disease state, age, sex, ethnicity and induction or alteration by xenobiotics. The CYP450 drug 
metabolising enzyme system is a major source of inter-individual variability in drug 
pharmacokinetics and toxicity (Jamei et al., 2009). 
The CYP450 2 family is the largest and most diverse CYP450 family, consisting of 16 genes 
in 11 subfamilies (Nelson, 2009). CYP2C19 (CYP2C subfamily), CYP2D6 (CYP2D 
subfamily) and CYP3A4 (CYP3A subfamily) enzymes are considered most pharmacologically 
significant, with regards to drug metabolism (Guengerich and Cheng, 2011). The CYP2D 
family consists of a single protein-coding gene, CYP2D6, that possesses more than 100 variant 
alleles (Zanger and Schwab, 2013). This enzyme metabolises more than 25% of clinically 
significant drugs including antidepressants, antihistamines and antipsychotics (Gardiner and 
Begg, 2006; Sistonen et al., 2007; Zanger and Schwab, 2013) (Table 1). The polymorphic gene 
is also known for its ability to metabolise drugs from certain illicit drug groups, namely 
amphetamine-type stimulants, opioid analgesics and sedative hypnotics (Druid et al., 1999; 
Jannetto et al., 2002; Kupiec et al., 2006; Koski et al., 2007; Crews et al., 2012; Neukamm et 
al., 2013). CYP2D6-mediated metabolism of these drugs is known to be a major source of 
variation in pharmacokinetics, and subsequently in drug effects (Jamei et al., 2009).  
Table 1: List of substances that are metabolised by the CYP2D6 enzyme. 
*Prodrug 
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**Commonly abused illicitly in South Africa                                       
(Legget 2002; Parry et al., 2004; Ingelman-Sundberg, 2005; Wilkinson 2005; Drugaware, 2006; da Silva et 
al., 2007; Dasgupta 2010; Peltzer et al., 2010; Dada et al., 2015) 
 
1.1.8 Variations in the CYP2D6 Gene and Resulting Metabolising Phenotypes  
 
The CYP2D6 gene has been extensively studied in certain population groups as it shows the 
greatest impact of genetic polymorphisms among all drug metabolising enzymes. This is 
reportedly due to the vast amounts of variants observed, the very few environmental influences 
and broad substrate selectivity (Zanger and Schwab, 2013). Genetic variation of 
pharmacogenetic interest in CYP2D6 is mainly in the form of single nucleotide polymorphisms 
(SNPs) and copy number variations (CNVs) (Allorge and Tournel, 2011).  
SNPs are defined as single-base variations at specific sites in a sequence. While the majority 
of SNPs are synonymous and have no significant effect on the functionality of a gene, there 
are some that occur in functionally important regions of genes that may lead to discernible 
differences in form and function of gene products (Kupiec et al., 2006; Allorge and Tournel, 
2011). CNVs are genomic rearrangements which cause partial or complete gene deletions or 
duplications of coding regions. They alter approximately 12% of the human genome, leading 
to gene dosage imbalance and coding sequence disruptions (Allorge and Tournel, 2011). When 
these genetic variations occur in genes that encode drug metabolising enzymes, they can 
eliminate, decrease or increase the activity of the enzyme and consequently result in certain 
phenotypic manifestations (Kupiec et al., 2006).  
Although there has not yet been complete characterisation of all the variant alleles of CYP2D6, 
according to Whirl-Carrillo et al. (2012), there are 196 variant alleles of the CYP2D6 gene, 
which define 163 different haplotypes. A haplotype is a set of DNA variations, or 
polymorphisms, that tend to be inherited together. Of these, over 15 haplotypes, including the 
most common CYP2D6*4 and CYP2D6*5, encode non-functional products (Pirmohamed and 
Park, 2001; Whirl-Carrillo et al., 2012). Other types of haplotypes that alter substrate 
specificity, increase or decrease activity have also been described (Pirmohamed and Park, 
2001).  
The polymorphisms in CYP450 genes are reported to produce distinct pharmacogenetic 
phenotypes categorised as poor, intermediate, extensive, and ultra-rapid metabolisers (Sajantila 
et al., 2010; Zanger and Schwab, 2013). The different phenotypes suggest complete lack of 
function, impaired functionality, normal functionality and gain in functional capacity, 
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respectively, for oxidation of the drug through manipulation of the genes that code for these 
enzymes (Zanger and Schwab, 2013). The different phenotypes are inferred from the genotypic 
data of the genes (Musshoff et al., 2010). For instance, ultra-rapid metabolisers (UM) result 
from the presence of more than two active alleles encoding for a certain CYP450 enzyme, 
which increases enzyme activity; conversely, poor metabolisers (PM) (where no enzyme 
activity is observed) lack functional alleles. Extensive metabolisers (EM) carry two functional 
alleles, which is representative of the majority of the population. Lastly, intermediate 
metabolisers (IM) carry alleles that partially decrease enzyme activity due to either complete 
lack of function in one allele with normal functionality in the other, or where a homozygous 
form exhibits a reduced function (Musshoff et al., 2010). The highest functioning CYP2D6 
allele typically predicts the phenotypic activity of the individual, based on the assumption of 
dominance (Owen et al., 2009). 
Individuals with PM associated variants for CYP2D6 may be at increased risk of suffering 
adverse side effects from increased levels of the drug in the body or from experiencing 
therapeutic failure due to the inability to effectively metabolise a prodrug to the active 
metabolite (Musshoff et al., 2010). In contrast, UMs experience significantly increased enzyme 
activity resulting either in the drug not remaining in the system long enough for the desired 
therapeutic effect or excessive production of an active metabolite following prodrug 
administration (Musshoff et al., 2010).  
Some haplotypes such as CYP2D6*1, CYP2D6*2 and CYP2D6*35 are known to exhibit 
normal enzyme activity while others such as CYP2D6*1xN and CYP2D6*2xN encode enzymes 
with increased activity and CYP2D6*10, CYP2D6*17, CYP2D6*29 and CYP2D6*41 with 
decreased activity (Masimrembwa et al., 1996; Marez et al., 1997; Zhou et al., 2017). 
CYP2D6*4, CYP2D6*5 and CYP2D6*6 where entire alleles are absent exhibit complete lack 
of function (Zhou et al., 2017).  
It must be noted that the association between genotype and phenotype is not straightforward 
(Sajantila et al., 2010). There are numerous allelic variants with unknown or uncertain in vivo 
function which could contribute to any metabolic phenotype. A study by Hicks et al. (2014), 
highlighted that although alleles are assigned a value of classification – no, decreased, normal 
or increased function – they do not take into account the degree of increased or decreased 
function or substrate-specific activity of the allele (Hicks et al., 2014). Based on phenotype 
studies, only individuals with lack-of-function alleles (PM) are significantly associated with an 
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expected phenotype (Sajantila et al., 2010). Overlapping of phenotypes is apparent and inter-
individual, inter-ethnic and other possible attributing factors should not be disregarded.   
1.1.9 CYP2D6 Variants in African Populations 
 
Population studies of drug metabolism have shown significant inter-population variance in 
polymorphic distribution of CYP2D6 activity and actively-related genetic materials (Abraham 
and Adithan, 2001). Few studies have been performed on the CYP2D6 variants in African 
populations, often leading to allelic frequencies from African-American populations being 
used to infer allelic frequencies in African populations (Alessandrini et al., 2013). A study by 
Alessandrini et al. (2013) illustrated why population-specific allelic frequencies should not be 
used interchangeably: while the frequency of CYP2D6*5 observed in Caucasian, Asian and 
African-American populations is below 10%, the frequency of this allele is noticeably higher 
in Mixed-Ancestry South African (17.7%) and South African Bantu (18.8%) populations (Lim 
et al., 2011). Further variation can be observed by comparing various African populations. For 
example, the frequency of the CYP2D6*5 allele in the South African Bantu populations is 
18.8%, which is reportedly more than three times that observed in the Kenyan Bantu 
populations (4.2%) (Alessandrini et al., 2013). For that reason, using the frequency of this PM 
allele in African-American or Kenyan Bantu populations is not a suitable proxy for the South 
African Bantu population. 
Studies in African populations have also yielded varied frequency results, suggesting regional 
variation among populations with a prevalence of poor metabolisers ranging from 0-19% 
(Abraham and Adithan, 2001) (Table 2). The wide variation observed in the CYP2D6 
phenotype in various African populations contradicts the previously, long-standing assumption 
that these populations were genetically homogenous (Masimirembwa et al., 1996). The 
influence of these genetic polymorphisms on CYP450 expression and function has made 
differentiating between suicide and/or accidental death, as well as acute versus chronic 
intoxication challenging.  
Studying genetically diverse populations can contribute immensely to advancements in the 
field of toxicogenetics and there are a number of benefits that research based on South African 
populations could offer to future studies (Warnich et al., 2011). These genetically diverse and 
admixed population groups, often a result of factors including non-random mating and genetic 
drift, should be utilised to elucidate the genetic variability contributing to the different types of 
drug responses observed (Warnich et al., 2011). 
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           Table 2: Frequencies from several different studies of CYP2D6 haplotypes observed in African populations. (Amended from Alessandrini et al., 2013).  
   
Haplotype *1 WT *2 EM *3 PM *4 PM *5 PM *6 PM *10 IM *17 IM 




















   




Kagimoto et al., 1990 Gaedigk et 
al., 1991 
Saxena et al., 
1994 
Yokota et al., 1993 Masimirembwa 
et al., 1996    
Type of Study Functional Association Functional Association Association Functional Functional 






Bantu (Sistonen et al., 2007) 8 Predicted 37.5 12.5 0 0 18.8 0 0 25.0 
 
Mixed Ancestry (Gaedigk & Coetsee, 
2008; Ikediobi et al., 2011) 
99, 67 Predicted, 
Association 
26.77 15.2 0 1.0-7.1 17.17 0 2.5 12.6 
 
Venda (Dandara et al., 2001; 
Matimba et al., 2008, 2009) 
9, 76, 81 Predicted, 
Association, 
Functional 
50.0 17.8-44.0 0 0-3.3 4.6 - 12.0-19.0 19-24.0 
 
Xhosa (Ikediobi et al., 2011; Wright 
et al., 2010) 
53, 109 Association, 
Predicted 
23.6 12.3 - 0-1.9 14.2 - 1.9 13.2 
 
South African (Dodgen et al., 2015) 100 Predicted 29.1 13.8 - 3.1 8.7 - - 19.4 
Namibia San (Sistonen et al., 2007) 7 Predicted 0 64.3 0 0 14.3 0 0 7.1 
Zimbabwe San (Matimba et al., 2008, 2009) 64 Association, 
Functional 
- - - 9.0 - - - 22.0 
 
Bantu (Masimirembwa et al., 1996; 
Matimba et al., 2008, 2009) 
23, 80 Predicted, 
Association, 
Functional 
- 63.0 0 0-2.5 3.8 - 0-5.6 20.0 
 
Zimbabwean (Dandara et al., 2001) 114 Predicted 47.0 13.0 0 2.0 4.0 - - 34.0 
            
"-" = Undetermined  WT = Wildtype EM =  Extensive Metaboliser IM = Intermediate Metaboliser PM = Poor Metaboliser UM = Ultra-rapid Metaboliser 
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 Table 2 continued: Frequencies from several different studies of CYP2D6 haplotypes observed in African populations. (Amended from Alessandrini et al., 2013). 
 
   
Haplotype *22 UNK *27 EM *29 IM *41 IM *43 EM *45 EM *1xN UM *2xN UM 
   
Variant 
location 































   
Published Marez et al., 1997 Raimundo et al., 2000 Marez et al., 
1997 
Gaedigk et al., 2005 Dahl et al., 1995 Johansson et 
al., 1993    
Type of 
Study 
Functional Association Functional Association Functional Association 




South Africa Bantu (Sistonen et al., 2007) 8 Predicted - - 6.3 0 - - 0 0 
 
Mixed Ancestry (Gaedigk & 
Coetsee, 2008; Ikediobi et 
al., 2011) 
99, 67 Predicted, 
Association 
- - 4.6 3.5 - - - 1.0 
 
Venda (Dandara et al., 2001; 
Matimba et al., 2008, 2009) 
9, 76, 81 Predicted, 
Association, 
Functional 
0 0 6.0 - 0 17.0 - - 
 
Xhosa (Ikediobi et al., 2011; 
Wright et al., 2010) 
53, 109 Association, 
Predicted 
- - 13.2 1.9 0.9 10.4 0 - 
 
South African (Dodgen et 
al., 2015) 
100 Predicted 0.5 - 3.6 3.6 1.5 - - 0.5 
Namibia San (Sistonen et al., 2007) 7 Predicted - - 0 0 - - 14.3 0 




0 - 2.0 - - - - - 
 
Bantu (Masimirembwa et al., 
1996; Matimba et al., 2008, 
2009) 
23, 80 Predicted, 
Association, 
Functional 
0 0 17.0 - 3.0 0 - 2.5 
 
Zimbabwean (Dandara et al., 
2001) 
114 Predicted - - - - - - - - 
            
"-" = Undetermined  WT = Wildtype EM =  Extensive Metaboliser IM = Intermediate Metaboliser PM = Poor Metaboliser UM = Ultra-rapid Metaboliser 
 
 
- 15 - 
1.2 Rationale 
 
Fatalities suspected to be due to adverse drug reaction is a prevalent problem faced in the 
Western Cape (van Heerden et al., 2009). This toxicity may be accidental, due to inadequate 
or enhanced metabolism/excretion. In cases such as these, drug toxicity may directly cause, or 
contribute to, death. 
Analyses requested by forensic pathologists within the Western Cape do not incorporate a 
molecular-based analysis component. Furthermore, there are currently no optimised and 
validated molecular-based assays designed for identifying genetically altered CYP450 genes in 
the local Forensic Pathology context. This makes it difficult to understand the influence genetic 
polymorphisms have on CYP450 expression and functionality among the deceased.  
Molecular assays to investigate genetic variation in CYP2D6 have been developed in other 
settings before and this has shown value in clinical applications with regards to pharmaceutical 
drugs (McElroy et al., 2000).  
A molecular assay to sequence genetic variants in CYP2D6 is hypothesised to also have value 
in a forensic post-mortem setting as many of the drugs in the Western Cape are metabolised by 
CYP2D6. A molecular autopsy, in which the molecular assay is utilised, may help resolve 
ambiguous toxicity cases and possibly provide more detailed reports that are able to help 
magistrates determine a manner of death. Before such an assay can be utilised by Forensic 
Pathology Services in the local context, an assay needs to be designed, optimised for use on 
post-mortem samples, thoroughly investigated through research, and then extensively 
validated, before it is carried out as a service. 
Drugs, therapeutic or illicit, which are commonly abused in the Western Cape will be the focus 
in assay development. While it is acknowledged that many enzymes contribute towards the 
metabolism of certain drugs, this is the first study in our context and will focus on one enzyme, 
CYP2D6. This may assist in interpretation of certain fatal drug intoxication cases, such as 
whether it was a suicide or accidental slow gradual intoxication due to an ineffective drug 
metabolising enzyme, in particular the CYP2D6 enzyme coding genes. Some cases of drug-
related fatalities admitted to SRM, may be the result of accidental adverse drug reactions 
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Although little research has been conducted on African populations in a forensic setting, it has 
been reported that South Africans have a unique distribution of polymorphisms in CYP2D6 
(Warnich et al., 2011). The current genomic challenge is to ascertain information on genetically 
diverse understudied populations, to translate this knowledge into forensic applications that 
can be applied to post-mortem investigations and to point out the challenges that can impact 
on the realisation of the benefits of toxicogenetics in South Africa (Warnich et al., 2011). This 
highlights the importance of designing an experimental assay, by drawing on literature of 
similar nature, to enable the sequencing of coding regions of CYP2D6, which will allow the 
interpretation of metabolising phenotypes in the local context.  
1.3 Aims and Objectives 
 
The aim of this study was to therefore design and optimise a molecular-based assay to evaluate 
genetic variation in toxicological-related fatalities. This assay hopes to eventually aid the 
procedures surrounding molecular autopsies for specific toxicity cases associated with 
CYP2D6 drug metabolism fatalities.  
To this end, the objectives were to: 
• Design an assay to amplify and sequence the exons of CYP2D6, by drawing on similar 
studies; 
• Optimise the assay in a local setting on DNA from healthy, control individuals;   
• Set up a standard operating procedure and analysis pipeline using the results generated 
from optimisation for in-house research use; 
• Apply the assay on DNA from two decedents admitted to Salt River Mortuary and 
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2. Materials and Methods 
 
2.1 Study design and ethics approval  
 
The research was a laboratory-based, prospective, cross-sectional study with a quantitative 
paradigm. This pilot study was focussed around design and optimisation, following the 
application of the optimised assay to demonstrate a proof of concept on a case example.   
The University of Cape Town Faculty of Health Sciences Human Research Ethics Committee 
(HREC) granted ethics approval for this study (HREC REF: 110/2017) (Appendix 1). 
An overview of the process by which designing and optimising the molecular-based assay took 















Figure 1: Flow diagram illustrating the dynamic process undertaken to optimise and design the 
molecular-based assay.  The assay was applied to two case examples from Salt River Mortuary.  
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2.2 Participants and sampling 
 
2.2.1 Control Participants 
 
For the study, a convenience sampling method was employed, whereby biological samples 
from four living, healthy participants of different populations groups based on race were used 
for the assay optimisation. This was deemed sufficient for several reasons, including: (i) the 
amount of DNA extracted from biological samples of a single individual would be enough for 
optimisation purposes; (ii) having more than one participant as a control highlights 
reproducibility; and (iii) emphasises the ease of accessibility to different population groups 
within South Africa in which several different variations are observed. Using DNA from living 
individuals, as opposed to deceased individuals, was deemed appropriate for the designing and 
optimisation of the molecular-based assay, due to ethical reasons – as obtaining informed 
consent and biological samples from the vulnerable deceased population needs to be strongly 
justified and was unnecessary for the optimisation phase of this study. Participation from 
control participants was voluntary and volunteers gave informed consent to participate 
(Appendix 2). Participants were all over the age of 18 years and each self-reported that they 
belonged to a different population group.  
2.2.2 Case Examples 
 
A biological sample from two decedents was sufficient to demonstrate a proof of concept. The 
identification process of suitable cases was performed in conjunction with a forensic 
pathologist, whereby the cause of death was associated with possible drug use/abuse. Informed 
consent from the decedent’s next-of-kin was received before any sample collection took place 
(Appendix 3).  
2.2.3 Sample Collection 
 
From the four control participants and the two decedents, a sample of 4 ml of blood was 
collected by using a venipuncture method and placing the blood into a purple top blood 
collection tube (BD VacutainerÒ, New Jersey, USA) containing ethylene-diamine-tetraacetic 
acid (EDTA) and stored at 4 degrees Celsius until further processing the same day. 
2.2.4 DNA Extraction 
 
Once the samples had been obtained, DNA extraction took place using the QIAampÒ DNA 
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Investigator Kit (QIAGEN, Hilden, Germany). The manufacturer’s protocol used, pertains to 
the isolation of total DNA from small volumes of whole blood (1 – 100 µl). A volume of 100 
µl of blood was initially used and in step two of the protocol 10 µl of ATL buffer was added, 
creating a final volume of 110 µl. In step nine, the MiniElute Column was centrifuged at 10,000 
revolutions per minute (rpm) for 1 minute 30 seconds. Lastly, in step 15, 50 µl of ATE buffer 
was added to elute the DNA from the membrane. 
2.2.5 DNA Quantification  
 
Nanodrop spectrophotometry was used to quantify the amount of total nucleic acids in the 
samples of interest (Desjardins and Conklin, 2010). A 2 µl sample of each DNA extract 
was pipetted onto the lower pedestal. The absorbance of light at 260 nm was measured and 
according to Beer’s Law, was proportional to the concentration of the sample medium 
(Gallagher, 1989). This enabled the quantification of the DNA present in the sample as 
well as the 260/230 and 260/280 purity ratios. This was carried out using the NanoDrop 
2000 spectrophotometer (Thermofisher Scientific, Massachusetts, USA). 
Quantitative PCR (qPCR) (Applied Biosystems 7500), was performed in-house in a parallel 
study, using the Quantifiler™ Trio DNA Quantification Kit (Applied Biosystems, California, 
USA), in order to establish whether degradation of the samples occurred. It was performed 
according to the manufacturer’s protocol. The trio kit quantifies a short and large fragment of 
DNA and by comparing the concentration of each fragment in a ratio (short/large), the 
degradation can be assessed. Degradation scores greater than 1 (>1) are representative of 
degraded samples.   
2.3 Assay Design  
 
2.3.1 Selection of Enzyme and Primer Design  
 
The CYP2D6 enzyme was selected as the enzyme of choice based on its relevance in the 
metabolism of drugs. Before primers could be designed, the CYP2D6 gene sequence was 
downloaded from Ensembl genome browser (http://www.ensembl.org) (Ensembl release 90, 
August 2017) – a website of an automated annotation of the human genome which provides a 
range of data that expands to include comparative genomics, variation and regulatory data. It 
identifies possible variants within coding and/or non-coding regions that can affect primer 
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design and primer suitability. Ensembl was used to locate the nine different exons within the 
CYP2D6 gene.  
Primer design is aimed at obtaining a balance between two definitive objectives – specificity 
and efficiency of amplification (Dieffenbach et al., 1993). Primers were designed in order to 
amplify and subsequently analyse the coding regions of the CYP2D6 gene. In order to target 
the exons within the gene, primers were designed so that they flanked the regions of interest, 
allowing for the exons to be amplified.  
The suitability of the primers was assessed using online primer design tools that included: (i) 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) (Accessed: 
29th January 2017) – a bioinformatic tool that identifies possible primers according to, 
parameters established, and the insertion of a region of interest; (ii) OligoAnalyzer 3.1 
(http://eu.idtdna.com/calc/analyzer) (Integrated DNA Technologies Inc., USA) – a software 
application that determines the properties of any oligo sequence as well as facilitate the 
intelligent design of assay conditions; and (iii) primer BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Accessed: 29th January 2017) – which assesses the 
primer pair specificity against a selected database. 
Exon 1 of the CYP2D6 gene was 1169 base pairs (bp), therefore, three sets of overlapping 
primers were designed (Exon 1 part 1, 2 and 3), such that each target amplicon length was less 
than 600 bp; as target DNA between 150 and 600 bp is one of the ideal primer properties in 
primer design for standard PCR (Dieffenbach et al., 1993). The forward primer for exon 1 part 
2 was chosen from the primer sets designed by Matimba et al. (2009). Exons 2 – 9 were all 
shorter than 600 bp; therefore, they were of an ideal length. All primers were designed such 
that their length was 18-24 bp, they contained a 50 – 65% GC content and maintained a melting 
temperature (Tm) between 50 – 60°C. Limited strong secondary structures, avoiding the 
presence of any heterodimers and avoiding false priming by verifying the primers specificity 
using Primer BLAST, such that the ideal parameters for primers were met (Vet and Marras, 
2005).  
Ensembl was used to explore the SNPs observed in the primer binding regions that have either 
been identified, or flagged as possible SNPs, in previous literature. Any SNPs that were found 
to be present in the population of interest at a frequency higher than 1%, were noted and the 
primer was shifted in order to exclude these variants. Once the primers met the ideal 
parameters, specificity was assessed using primer BLAST and primer sets were deemed 
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adequate only if the amplicon of interest would be amplified, with no problematic non-specific 
products being produced (Ye et al., 2012).  
The primers were ordered (IDT, Cape Town, South Africa) and were re-suspended in 1 x Tris-
EDTA (TE) buffer (Sigma-Aldrich, St. Louis, USA) to a stock concentration of 100 µM. 
 Table 3: Primer sets designed to amplify the exons in CYP2D6.  
Primer Set Primer 
Direction 








1. Exon 1 
part 1 
Forward GCCATCATCAGCTCCCTT 18 55.6 54.9 439 
Reverse CCCAAACCTGCTTCCCCTT 19 57.9 57.9 
2. Exon 1 
part 2 
Forward CCCTACCAGAAGCAAACA (Matimba 
et al., 2009) 
18 50.0 52.0 597 
Reverse CCTATTTGAACCTTGGACGA 20 45.0 52.1 
3. Exon 1 
part 3 
Forward CTTCCACCTGCTCACTCC 18 61.1 55.3 314 
Reverse TCTGTCTCTGTCCCCACC 18 61.7 56.1 
4. Exon 
2&3 
Forward GTGGATGGTGGGGCTAAT 18 55.6 54.6 483 
Reverse ACTCCTCGGTCTCTCGCT 18 61.1 57.7 
5. Exon 4 Forward CCCGTTCTGTCTGGTGTAG 19 57.9 54.9 266 
Reverse AGCCTCCCCTCATTCCTC 18 61.1 56.3 
6. Exon 
5&6 
Forward GTTCTGTCCCGAGTATGC 18 55.6 52.7 334 
Reverse CCTGACACTCCTTCTTGC 18 55.6 52.9 
7. Exon 7 Forward CATAGGAGGCAAGAAGGAG 19 52.6 52.1 382 
Reverse TGGTGGCATTGAGGACTA 18 50.0 53.1 
8. Exon 8 Forward ATCCTAGAGTCCAGTCCC 18 55.6 52.3 534 
Reverse ACTACCACATTGCTTTATTGTAC 23 34.8 51.0 
9. Exon 9 Forward TATCACCCAGGAGCCAGG 18 61.1 56.3 520 
Reverse CCCACATGCCAGGACAAT 18 55.6 55.4 
* Primer design tools included: (i) Primer3Plus (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi) (Accessed: 29th January 2017); (ii) OligoAnalyzer 3.1 
(http://eu.idtdna.com/calc/analyzer) (Integrated DNA Technologies Inc., USA); and (iii) primer BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Accessed: 29th January 2017). 
 
2.3.2 Sanger Sequencing as a Method of Choice 
 
Genotyping is the process of determining genetic variations at specific loci within an 
individual. Sequencing, is the process of identifying the exact sequence of a length of DNA 
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(Sanger et al., 1977). Sequencing was the method of choice as the focus of interest was not just 
certain genetic variants that are found in commonly studied populations but the entire sequence 
of understudied populations. In order to have identified genetic variants that may not be found 
in other population groups but are common in the population group of interest, Sanger 
sequencing was considered ideal. 
2.4 Assay Optimisation 
 
2.4.1 PCR Optimisation 
 
PCR optimisation was initially performed by use of a temperature gradient PCR to establish 
the optimal annealing temperature for each primer set. The reaction components for each PCR 
included 1 X Taq polymerase 2X Ready Mix, 0.2 µM of each of the forward and reverse primer 
and 50 ng of DNA template in a final volume of 25 µl. AccuGene® molecular biology grade 
water (Lonza, Rockland, USA) was added to the negative control (no template control - NTC) 
instead of template DNA.  
Three different Taq polymerase ready mixes were also investigated whereby temperature 
gradient PCRs for part 1 of exon 1 were set up using each of the following Taq polymerases 
respectively; (i) Taq DNA Polymerase Master Mix Red kit (AMPLIQON, Odense, Denmark); 
(ii) EmeraldAmp® MAX HS PCR Master Mix (Takara Biotechnology, Mountain View, USA); 
and (iii) GoTaq® Green Master Mix (Promega, Madison, USA). The GoTaq polymerase ready 
mix was selected for the subsequent PCR reactions as it produced PCR products with the best 
yields and with the least non-specificity over the range of annealing temperatures.  
PCR was performed in the Bio-Rad T100 Thermocycler (Bio-Rad Laboratories, USA) and 
thermal cycling was according to standardised cycling conditions: initial denaturation step at 
95°C for 5 minutes; then for 30 cycles thereafter, a three-step process consisting of denaturation 
at 95°C for 30 seconds; annealing at temperatures ranging from 49°C - 65°C for 30 seconds 
and elongation at 72°C for 30 seconds was completed. A final elongation step at 72°C for 5 
minutes was completed accounting for any remaining single-stranded DNA still needing to be 
extended. The lowest annealing temperature in the gradient was established by subtracting 5°C 
from the predicted Tm of the primers within the primer set. 
If non-specific products were observed, the PCR was further optimised by repeating the 
temperature gradient at higher annealing temperatures. The final annealing temperature 
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selected for each primer set was based on yield and specificity of the PCR products at each of 
the temperatures within the gradient. For exon 1 (part 1 and 3) and exon 9, a final annealing 
temperature of 62.9°C was used, while the rest used a final annealing temperature of 55.3°C.  
2.4.2 Agarose Gel Electrophoresis 
 
Subsequent to each PCR, agarose gel electrophoresis was performed to visualise PCR products.  
A 1% (w/v) agarose gel was made by dissolving agarose powder (SeaKemÒ LE, Rockland, 
USA) in 1X Tris-Borate-EDTA (TBE) buffer (Sigma-Aldrich, St. Louis, USA). Initially, two 
different nucleic acid gel stains, SYBRÒ Safe (Thermofisher Scientific, Massachusetts, USA) 
and GelRedTM Nucleic Acid Gel Stain (Biotium Inc., California, USA), were investigated and 
the SYBRÒ Safe was selected for subsequent use. A volume of 7.5 µl of SYBRÒ Safe nucleic 
acid gel stain was added to the agarose gel for DNA visualisation. The gel was poured into a 
casting tray with a comb in position and allowed to set. Once the gel had set, it was transferred 
into a gel tank, filled with 1X TBE buffer. An amount of 5 µl of Quick-LoadÒ 50 bp Ladder 
(New England BioLabsÒ Inc., Ipswich, USA) was loaded into the first well, followed by 5 µl 
of the NTC PCR product into the second well. A volume of 5 µl of each PCR product was 
subsequently loaded into consecutive wells of the gel. The gel tank was then connected to the 
Bio-Rad PowerPacTM Basic (Bio-Rad Laboratories, Hercules, USA) and subjected to 
electrophoresis at 100 V for 80 minutes. The gel was visualised under UltraViolet (UV) light 
on a Syngene Chemi Genius Bio-Imaging System (Syngene, Gurugram, India).   
2.4.3 Sanger Sequencing 
 
Before sequencing commenced, a post-PCR clean-up step was performed, using a Nucleofast 
96 well PCR plate (Macherey Nagel, Düren, Germany).  The manufacturer’s protocol was 
implemented on a Tecan EVO 150 robotic workstation (Tegan Trading, Switzerland). This 
purifying step achieved removal of unincorporated dNTPs, primers, short failed PCR products 
and salts in order to minimise interference with results.  
DNA sequencing was performed using the BigDye Terminator v3.1 cycle sequencing kit 
(Applied Biosystems, California, USA). Sequencing was performed on each of the 9 exons 
within the CYP2D6 gene (Sanger et al., 1977). PCR products of exon 1 (part 1, 2 and 3) were 
sequenced with their respective forward and reverse primers in order for the entire exon 
including overlapping regions to be sequenced and/or to identify if there was a possible deletion 
of the entire gene. The PCR products of the remaining exons were sequenced with either their 
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corresponding forward or reverse primer. The primer that is positioned further from the region 
of interest was chosen for sequencing, to allow for the standard noise at the beginning of the 
sequencing strand to not overlap with the region of interest. Certain PCR products were 
sequenced in duplicate to confirm the presence of potentially novel variants. The Sanger 
sequencing was performed at the Central DNA Sequencing Facility, University of 
Stellenbosch, Western Cape; according to their in-house protocol.   
2.4.4 Amendment to Protocol During Optimisation 
 
During optimisation, the primer sets used were amended as control 4 (and a case sample, as 
later identified) had three SNPs within the primer binding region, that did not allow primer 
binding to occur (see Chapter 3 section 3.1.2). During primer design,  these variations were 
noted, but had extremely low frequencies in the background population. However, due to their 
presence, the forward primer of exon 1 part 2 could not bind; as such, the primer set was 
amended. The amended primer set (new exon 1 part 1) now consisted of the original exon 1 
part 1 forward primer (5’-GCCATCATCAGCTCCCTT-3’) but the exon 1 part 2 original 
reverse primer (5’-CCTATTTGAACCTTGGACGA-3’), which covered a region of 954 bp. 
The new primer set was assessed using bioinformatics, and optimised according to the methods 
described above (Table 4).   
Table 4: Amended primer set exon 1 part 1 (with original exon 1 part 1 forward primer and exon 1 
part 2 reverse primer). 
Primer Set Primer 
Direction 








1. Exon 1 
part 1 
Forward GCCATCATCAGCTCCCTT (unchanged) 18 55.6 54.9 954 
Reverse CCTATTTGAACCTTGGACGA (originally 
exon 1 part 2 reverse primer) 
20 45.0 52.1 
 
2.4.5 Data Analysis 
 
The sequence data was analysed using two different DNA sequencing software platforms. 
ChromasLite version 2.4.4 was used to view the resulting electropherograms and identify 
known or possible novel variants in the sequenced gene (Technelysium, South Brisbane, 
Australia). The sequencing results from the participants were also compared to the reference 
CYP2D6 sequence, by aligning the sequences, using BioEdit version 7.2.6 Sequencing 
Alignment Editor and Analysis Program (Hall, 1999). ClustalW was used for multiple 
sequence alignment with a bootstrap of a 1000. SNPs, Indels and other variations were recorded 
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and compared to the literature and to genome data available on Ensembl to assess their 
functional significance and/or novelty.  
The resulting optimised assay was then written into a standard operating procedure, which is 
being published in-house and is available upon request. 
2.5 Assay Application 
 
A volume of 500 µl of blood was aliquoted from each of the tubes (Grey, Red and Purple top 
tubes) that were collected at autopsy for toxicological analysis (performed in-house in parallel 
study). Sample preparation in the form of acetonitrile protein precipitation was performed on 
the aliquots, before they underwent screening by means of liquid chromatography-tandem mass 
spectrometry (LCMSMS) analysis using a Shimadzu Prominence (Tokyo, Japan) High 
Performance Liquid Chromatography system coupled to a AB SCIEX API 3200 Q-TRAP Mass 
Spectrometer (Massachusetts, USA), that operates on the AB SCIEX MasterViewTM software 
(Massachusetts, USA). The blood from which the samples that underwent a toxicological 
screen were aliquoted, remained under storage at 4˚C until DNA extraction was performed. 
The toxicological analysis was performed in-house by the Division of Clinical Pharmacology, 
University of Cape Town. 
The optimised assay was then applied to the DNA extracted from the cases (see Chapter 2 
section 2.2.4), using the developed standard operating procedure. Upon analysis of sequencing 
results, PCR products of exons 4, 5, 6 and 9 were sequenced in duplicate, using their opposite 
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3. Results 
 
3.1 Assay Optimisation 
 
Assay optimisation was performed using DNA from four healthy, control individuals. DNA 
was extracted and quantified successfully (Table 5). In all instances, the first elution of DNA 
was used for optimisation. An A260/A280 ratio above 1.80, in Table 5, indicates relatively pure 
samples with little, if any, protein contamination. The A260/A230 ratios were more variable, 
however, the samples used were considered adequate for further use. 
Table 5: DNA quantification results of the four control’s blood samples, using a NanoDrop 2000 
spectrophotometer. 






Control 1 – Sample A 







Control 2 – Sample A 







Control 3 – Sample A 




  1.98 
1.49 
0.81 
Control 4 – Sample A 







*Sample A – First elution (used for optimisation); Sample B – Second elution. 
3.1.1 PCR Optimisation 
 
Following the selection of the CYP2D6 enzyme, nine sets of primers were designed to amplify 
and sequence the exons within the CYP2D6 gene. To this end, temperature gradients were 
performed for each region of the CYP2D6 gene. Figure 2 shows the temperature gradient for 
exon 1 part 1 as visualised on a 1% agarose gel, and is a representation of the typical results 
obtained for all nine regions (which can be found in Appendix 4). The final annealing 
temperature selected for each primer set was based on yield and specificity of the PCR products 
at each of the temperatures within the gradient.  
During the first temperature gradient (exon 1 part 1), three different Taq polymerase ready 
mixes and two different visualisation dyes were investigated (Figure 2). The GoTaq 
polymerase ready mix produced PCR products with the best yields and with the least non-
specificity over the range of annealing temperatures (Figure 2C) and was thus selected for all 
the subsequent PCR reactions. 
 
 






























































































Figure 2: Gel electrophoresis showing PCR products of Exon 1 part 1 using three different Taq 
polymerases. A) Taq DNA Polymerase Master Mix Red (AMPLIQON, Odense, Denmark); B) 
EmeraldAmp® MAX HS PCR Master Mix (Takara Biotechnology, Mountain View, USA); and C) GoTaq® 
Green Master Mix (Promega, Madison, USA). The gel was visualised under UltraViolet (UV) light on a 
Syngene Chemi Genius Bio-Imaging System (Syngene, Gurugram, India). MWM: 50bp molecular weight 










The agarose gels prepared using SYBRÒ Safe nucleic acid gel stain (Figure 2B and 2C) were 
preferred to the gel prepared using GelRedTM nucleic acid gel stain (Figure 2A), as clearer 
staining of the MWM and a decreased background fluorescence excitation was observed in the 
gels prepared with SYBRÒ Safe. SYBRÒ Safe was used in subsequent agarose gels. 
Overall, for exon 1 part 3 and exon 9, a final annealing temperature of 62.9°C was used for 
PCR, while the rest of the exon regions incorporated an annealing temperature of 55.3°C. In 
order to test the assay further, PCR of all exon regions and subsequent agarose gel 
electrophoresis was performed on DNA from the four controls. The presence of bands at the 
correct position on the gel based on the known amplicon size was representative of positive 
amplification. Figures 3 and 4 represent PCR amplification of exon 8 and exon 1 part 2, 
respectively. Agarose gel images of the remaining exon regions can be observed in Appendix 

















Figure 3: Gel electrophoresis showing amplification of Exon 8 in the four different controls and case 
1. The gel was visualised under UltraViolet (UV) light on a Syngene Chemi Genius Bio-Imaging System 
(Syngene, Gurugram, India). MWM: 50bp molecular weight marker; NTC: No Template Control; 1: Control 
1; 2: Control 2; 3: Control 3; 4: Control 4 and C: Case 1.  
 
Amplification of exon 1 part 2 was successful in all the controls except for control 4 (Figure 
4). Following repetition of PCR and agarose gel electrophoresis, the same result was observed, 
which eliminated pipetting error as the cause for lack of amplification. It was thus hypothesised 
that there may be genetic variation in the primer binding region, which was then investigated 






























Figure 4: Gel electrophoresis showing amplification of Exon 1 part 2 in the four different controls and 
case 1. The gel was visualised under UltraViolet (UV) light on a Syngene Chemi Genius Bio-Imaging 
System (Syngene, Gurugram, India). MWM: 50bp molecular weight marker; NTC: No Template Control; 
1: Control 1; 2: Control 2; 3: Control 3; 4: Control 4 and C: Case 1.  
3.1.2 Sequencing Optimisation 
 
The PCR products from the four control participants were sequenced and analysed in order to 
(i) confirm whether the amplified PCR products were indeed the regions of interest; (ii) to 
confirm which primer was optimal for sequencing (Figure 5); and (iii) to identify the reason 














Figure 5: Two electropherograms representing a portion of Exon 2&3. (A) Sequence using the forward 
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Reference 
 Control 4 
In Figure 5A, the sequenced region shows background noise, which is not ideal; at worst, it 
may contribute to the incorrect calling of SNPs. However, Figure 5B, which represents the 
same region but sequenced with the reverse primer, shows a clean electropherogram. 
Therefore, the primers in Table 6, were the primers chosen for subsequent sequencing. 
However, for five of the regions, two sequencing reactions were preformed, one with the 
forward primer and one with the reverse primer, as these regions either contained an 
insertion/deletion; or they were overlapping regions of the exon (i.e. exon 1). 
Table 6: The selected primers for subsequent sequencing of each exon region. 
Primer set Forward Reverse 
1. Exon 1 part 1 X X 
2. Exon 1 part 2 X X 
3. Exon 1 part 3 X X 
4. Exon 2&3  X 
5. Exon 4 X X 
6. Exon 5&6 X  
7. Exon 7 X  
8. Exon 8  X 
9. Exon 9 X X 
                   *X – Represents which primer was selected for sequencing. 
It was hypothesised that the lack of amplification seen in the region of exon 1 part 2 in control 
4 was due to a null allele. To confirm this, exon 1 parts 1 and part 3 were sequenced in both 




Figure 6: A sequence alignment of a portion of exon 1 part 1 in control 4 in the reverse direction. 
Illustrating variations within the primer binding region of exon 1 part 2.  
 
In Figure 6, the sequence of DNA in control 4 has been compared to the reference sequence 
and the primer region of exon 1 part 2 has been highlighted; it shows that there was indeed 
variation present within the primer binding region of exon 1 part 2. There were three nucleotide 
changes: at positions 73 and 74 (c.180+52_180+53delGAinsCC) and at position 79 
(c.180+47T>C). Therefore the presence of these three homozygous G/G variations likely 
prevented the forward primer of exon 1 part 2 binding to this region during PCR, thus 
explaining the null allele. As a result, the primer sets used were amended. 
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It should be noted that these variations were extremely rare, which was why the site was 
initially deemed to be suitable for primer binding. The amended primer set (new exon 1 part 1) 
was amended to consist of exon 1 part 1 forward primer (5’-GCCATCATCAGCTCCCTT-3’) 
and exon 1 part 2 reverse primer (5’-CCTATTTGAACCTTGGACGA-3’), which covered a 
region of 954 bp.  
3.2 Assay Application 
 
3.2.1 Toxicological Screening Results 
 
Blood collected from the two decedents was sent for a toxicological screening and the Table 7 
summarised the substances found (Table 7). Full reports are in Appendix 6.  




Case 1 LCMSMS Amitriptyline, Nortriptyline, Protriptyline, Citalopram and 
Paracetamol 
Case 2 LCMSMS Fluoxetine, Ephedrine, Doxylamine and Diphenhydramine 
*LCMSMS – Liquid Chromatography Mass Spectrophotometry Mass Spectrophotometry.  
3.2.2 DNA Quality Check 
 
Subsequent to DNA extraction from blood samples of the two decedents, DNA quantification 
was performed using Nanodrop spectrophotometry. Quantitative PCR (qPCR) was also 
performed in order to establish whether the samples were degraded; whereby the higher the 
degradation index (>1), the more degraded the sample. Values close to 1, which was the 
observed in both cases, indicate relatively little degradation. The results of DNA quantification 
and the degradation index of each case are summarised in Table 8. 
Table 8: DNA quantification results and degradation indices of the two cases, using a NanoDrop 2000 
spectrophotometer and Applied Biosystems 7500 qPCR. 
 
The optimised assay was then applied to the two cases. Figure 7 is a representation of an 
agarose gel showing amplification of each region in case 2. Initially, the original primer sets 
Cases DNA concentration 
(ng/µl) 
A260/A280 ratio A260/A230 ratio Degradation 
Index 
Case 1 – Sample 1 51.2 1.93 2.10 0.96 
Case 2 – Sample 1 58.7 1.83 1.86 0.82 
 
 

























(n=9) were used to amplify the DNA from the two case examples; however, exon 1 part 2 failed 


















Figure 7: Gel electrophoresis showing amplification of eight regions within the CYP2D6 gene, in case 
2. MWM: 50bp molecular weight marker; 1.1: Exon 1 part 1; 1.2: Exon 1 part 2; 1.3: Exon 1 part 3; 2&3: 
Exon 2&3 4: Exon 4; 5&6: Exon 5&6; 7: Exon 7; 8: Exon 8 and 9: Exon 9. 
 
In case 2 only, the new primer combination for exon 1 part 1 was then used for amplification 
















Figure 8: Gel electrophoresis showing amplification of the new Exon 1 part 1 region. Region in Exon 1 
part 1 in CYP2D6 gene in case 2, using the amended primer pair. 1.1: Exon 1 part 1. 
 
After successful amplification, each region was sequenced and aligned with the reference 
sequence (Ensembl release 90, August 2017 ) and several variations were observed. For 
example, in Figure 9, the reference sequence of a region of exon 1 part 1 has been aligned with 
the same region in both case 1 and case 2; in both the forward and reverse direction. A variation, 
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A 
B 
more specifically an insertion (c.137_138insT) was observed, disrupting the sequence and 














Figure 9: Two sequence alignments of a portion of Exon 1 part 1 in case 1 and 2. (A) forward direction 
and (B) reverse direction, illustrating a variation identified as an insertion (137_138insT). 
 
3.2.3 Summary and Analysis of Variants 
 
All variations observed during the analysis of the sequence were further investigated using 
Ensembl (Release 90, August 2017) and literature, to assess their functional significance. The 
contribution of the variations to haplotypes was also investigated and a summary of all variants 
observed for case 1 and 2 can be observed in Table 9 and 10, respectively. The reported minor 
allele frequencies are those of the variations observed in a combined world population as there 
is no data for South African ‘Mixed Ancestry’ populations. The frequencies were obtained 
from Ensembl, representative of data from 1000 Genomes Project Phase 3 (The 1000 Genomes 
Project Consortium, 2015) and gnomAD (version 2.0.2, October 2017). Enzyme activity of the 
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Table 9: Frequencies and positions of CYP2D6 genetic variants, their associated amino acid changes, 
haplotypes and effects on enzyme activity in Case 1. 
*HGVS – Human Genome Variation Society Nomenclature. 
 
The variation 137_138insT was heterozygous, therefore causes decreased functionality of one 
allele. The remaining heterozygous SNPs that have also contributed to haplotypes, namely; 
CYP2D6*1D, *27, *43 and *86, all possess normal or unknown functionality. The combination 
of one allele with a known decreased activity (*13) and an allele with either a normal or 
unknown activity, infers either an EM or IM phenotype (Figure 10), however, without parental 













Haplotype Nucleotide Change 












 rs28371696 CYP2D6*43 77G>A G/A R26H 1% Normal 
rs774671100 CYP2D6*13 137_138insT -/T - <0.1% Decreased 
rs28371718 CYP2D6*1D 2575C>A (801C>A) C/A - 2.3% Normal 
rs77913725 CYP2D6*86 2606G>A (832G>A) G/A E278K  0.4% Unknown 
rs1135828 2610T>A (836T>A) T/A M279K 0.4% 
rs769157652 CYP2D6*27 3853G>A (1228G>A) G/A E410K 0.1% Normal 
Additional SNPs 
rs769258 - 31G>A G/A V11M 1.7% Unknown 
rs151226748 - 102A>G A/G - <0.1% Unknown 
rs1080995 - 214G>C (180+34G>C) G/C - 30.7% Unknown 
rs1080996 - 221C>A (180+41C>A) C/A - 30.7% Unknown  
rs1080997 - 223C>G (180+43C>G) C/G - 30.7% Unknown  
rs1080998 - 227T>C (180+47T>C) T/C - 30.7% Unknown  
 rs29001518 - 232G>C (180+52G>C) G/C - 30.7% Unknown 
rs28695233 - 233A>C (180+53A>C) A/C - 30.7% Unknown 
rs17002853 - 2466T>C (692T>C) T/C L231P <0.1% Unknown 
rs17002852 - 2470T>C (696T>C) T/C - 0.7% Unknown 
rs28371721 - 2661G>A (843+44G>A) G/A - 1.8% Unknown 
rs59421388 - 3183G>A (1012G>A) G/A - 2.9% Unknown 
rs1135835 - 4131A>G (1408A>G) A/G A470T 0.1% Unknown 
rs1135839 - 4166T>C (1443T>C) T/C - - Unknown 
rs28371736 - 4172C>T (1449C>T) C/T - <0.1% Unknown 
rs1135840 - 4180G>C (1457G>C) C/C S486T 59.9% Increased 
rs61731577 - 4193T>C (1470T>C) T/C - <0.1% Unknown 
 
 






















Figure 10: Genotype/Phenotype association and the effects in CYP2D6 activity. (Taken from Balogh 
et al., 2011). *Black box – Wild type alleles (Normal function), White box – Null alleles (No function), 
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Table 10: Frequencies and positions of CYP2D6 genetic variants, their associated amino acid changes, 
haplotypes and effects on enzyme activity in Case 2.  
*HGVS – Human Genome Variation Society Nomenclature. 
 
The same variation 137_138insT observed in case 1 was also observed in case 2; this renders 
one allele non-functional. Haplotypes with normal or unknown functionality were also 
observed in case 2 (Table 10). However, the presence of homozygous SNPs forming the 
CYP2D6*17 haplotype, meant that both alleles had decreased activity. In this case, it was 
inferred that the individual possessed an IM phenotype (Figure 10), as both alleles were 
identified as having decreased activity. 
RefSNP (rs) 
Number  
Haplotype Nucleotide Change M33388.1 











rs28371696 CYP2D6*43 77G>A G/A R26H 1% Normal 









rs1058164 1661G>C (408G>C) C/C - 59.9% 
rs16947 2850C>T (886C>T) T/T R296C 35.9% 
rs1135840 4180G>C (1457G>C) C/C S486T 59.9% 
rs28371718 CYP2D6*1D 2575C>A (801C>A) C/A - 2.3% Normal 
rs77913725 CYP2D6*86 2606G>A (832G>A) G/A E278K  0.4% Unknown 
rs1135828 2610T>A (836T>A) T/A M279K 0.4% 
rs769157652 CYP2D6*27 3853G>A (1228G>A) G/A E410K 0.1% Normal 
Additional SNPs 
rs769258 - 31G>A G/A V11M 1.7% Unknown 
rs151226748 - 102A>G A/G - <0.1% Unknown 
rs1080995 - 214G>C (180+34G>C) C/C - 30.7% Unknown 
rs1080996 - 221C>A (180+41C>A) A/A - 30.7% Unknown 
rs1080997 - 223C>G (180+43C>G) G/G - 30.7% Unknown 
rs1080998 - 227T>C (180+47T>C) C/C - 30.7% Unknown 
rs796532118 - 180+52_180+53delGAinsCC G/G and G/G - - Unknown 
rs1081000 - 245G>A (180+65G>A) A/A - 30.7% Unknown 
rs28371699 - 310G>T (180+130G>T) T/T - 63.2% Unknown 
rs28371702 - 843T>G (181-41T>G) G/G - 63.0% Unknown 
rs17002852 - 2470T>C (696T>C) T/C - 0.7% Unknown 
rs28371721 - 2661G>A (843+44G>A) G/A - 1.8% Unknown 
rs59421388 - 3183G>A (1012G>A) G/A - 2.9% Unknown 
rs1985842 - 3384A>C (1173+40A>C) C/C - - Unknown 
rs4987144 - 3790C>T (1174-9C>T) C/T - - Unknown 
rs1135835 - 4131A>G (1408A>G) A/G A470T 0.1% Unknown 
rs1135837 - 4158G>C (1435G>C) G/C G479R <0.1% Unknown 
rs1135838 - 4164T>G (1441T>G) T/G F481V - Unknown 
rs1135839 - 4166T>C (1443T>C) T/C - - Unknown 
rs28371736 - 4172C>T (1449C>T) C/T - <0.1% Unknown 
rs61731577 - 4193T>C (1470T>C) T/C - <0.1% Unknown 
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4. Discussion 
 
The main purpose of this research project was to design and optimise a molecular-based assay 
to aid the procedures surrounding molecular autopsies for specific toxicity cases. In addition 
to this, the assay was applied to DNA obtained from blood samples of two decedents admitted 
to Salt River Mortuary, in order to demonstrate a proof of concept. Apart from the assay being 
applied to DNA from the two cases, blood samples were also sent for toxicological screening, 
in order for interpretation to be attempted.  
4.1 Case 1  
 
4.1.1 Case History 
 
A 45-year-old Coloured female, was admitted to Groote Schuur Hospital complaining about 
acute shortness of breath. Upon assessment, she was found to be clinically cyanotic and 
presented with features of airway obstruction. The deceased, while undergoing medical 
intervention, went into cardiac arrest. Cardiopulmonary resuscitation was performed; however, 
she developed asystole and was declared dead 20 minutes thereafter. The manner of death was 
a suspected suicide-overdose, as she had a history of over-the-counter medication abuse. It was 
known that she had hypertension, diabetes, major depression and anxiety. A post-mortem was 
performed by a Forensic Pathologist and the following findings were deduced: (i) History of 
diabetes and hypertension with evidence of target organ damage and (ii) Critically stenosed 
left anterior descending coronary artery with superadded fresh occlusive thrombus. Given the 
significance of the coronary artery stenosis, it was concluded that the cause of death was 
myocardial infarction.  
Consent was obtained from the next-of-kin to collect blood for DNA analysis and toxicological 
screening. The following drugs and/or metabolites were detected: amitriptyline, nortriptyline, 
protriptyline, citalopram and paracetamol (Table 6 and Appendix 6). Several genetic variants 





- 38 - 
4.1.2 Relationship between an Identified Drug and the Predicted Phenotype  
 
CYP2D6 is reported to play a role in metabolism of amitriptyline and its active metabolite 
nortriptyline, as well as protriptyline and citalopram. The metabolic pathway of amitriptyline, 
which is a commonly abused tricyclic antidepressant (TCA), is presented in Figure 11 
(Shenouda and Desan, 2013).  It has been used in the treatment of depression for many years 
and is still widely administered (Jornil and Linnet, 2009). Amitriptyline, known to be one of 
the most studied TCAs, is metabolised by several CYP450 enzymes, most importantly 
















Figure 11: Major metabolic pathways of amitriptyline and nortriptyline and the CYP450 enzymes 
reported to mediate their metabolism. (Taken from Jornil and Linnet, 2009). 
 
In the metabolic pathway of amitriptyline, CYP2C19 aids its metabolism to its active 
metabolite nortriptyline, while CYP2D6 is responsible for more than 80% of the metabolism 
of nortriptyline to demethyl nortriptyline and E-10-OH-nortriptyline (Jornil and Linnet, 2009) 
(Figure 11).  Recently, there has been a major focus on genetic variation within the CYP450 
system for the metabolism of TCAs (Jornil and Linnet, 2009). This is attributed to the 
considerable inter-individual variation of drug metabolism; and the risk of intoxication even 
from a standard dose. This resulting from the narrow therapeutic index associated with such 
central nervous system (CNS) drugs (Jornil and Linnet, 2009; Zhou, 2009). Jornil and Linnet 
(2009), also noted the importance of investigating the metaboliser phenotype with respect to 
CYP2D6, as an association between an altered metaboliser phenotype and an increased plasma 
concentration of antidepressants, such as amitriptyline, was observed. The importance of a 
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molecular analysis has been identified, and whether to combine therapeutic drug monitoring 
with a genetic analysis, is a question that is frequently debated (Jornil and Linnet, 2009). 
In case 1, the decedent possessed several variants, which contributed to a number of different 
haplotypes, namely: CYP2D6*13, *1D, *27, *43, and *86. One of the most significant variants 
observed in the deceased was an insertion (137_138insT). The 137_138insT insertion causes a 
frameshift in the open reading frame, which inherently abolishes enzyme activity (Panserat et 
al., 1995). This variant results from the hybridisation of the CYP2D6 and CYP2D7 genes. The 
hybrid gene shares a CYP2D7-derived exon 1, which differs from CYP2D6 gene by a single 
nucleotide insertion (T-insertion), thereby differing in respect to the region in which CYP2D7 
switches to CYP2D6 (Panserat et al., 1995). This variant is associated with both the 
CYP2D6*13 and CYP2D6*15 haplotypes. However, the presence of the additional variants 
c.696T>C, c.801C>A, c.832G>A and c.836T>A in this case, are associated with a CYP2D7 
gene conversion in exon 5, which suggests the haplotype CYP2D6*13E (Gaedigk et al., 2010).  
The CYP2D6*13 haplotype is of clinical significance as it often causes altered drug clearance 
and drug response (Zhou, 2009). This functionally inactive allele, according to gnomAD 
(version 2.0.2 – October 2017), occurs in four out of every 14,892 individuals (0.03%) within 
the African population, which is higher than that seen in any other population group (gnomAD, 
version 2.0.2 – October 2017). The other haplotypes present, CYP2D6*1D (7.3%), 
CYP2D6*27 (0.1%), CYP2D6*43 (2.3%) and CYP2D6*86 (0%), which are associated with a 
normal or unknown enzyme activity are, found in African populations in varying frequencies 
(gnomAD, version 2.0.2 – October 2017).  
The deceased was characterised as either an IM or EM phenotype after considering all the 
possible options/combinations of haplotypes on the two alleles (Zhou, 2009) (Figure 12). In 
any given situation, the presence of the CYP2D6*13 haplotype would automatically render one 
allele inactive (Panserat et al., 1995) (Figure 12). Therefore, for an EM phenotype to result, the 
alternate allele would need normal or increased functionality (Figure 12). Equally, if the 
alternate allele presented with a decreased functionality an IM phenotype would result. 
However, our prediction of the phenotype in this case was limited, as without segregation 
analysis being performed, or unknown significance of identified SNPs, these are considered 
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Figure 12: Illustration of the possible phenotypes based on combinations of the different decreased or 
unknown activity haplotypes observed in case 1. 
 
Typically, these predicted phenotypes suggest that a drug found within the blood of the 
deceased, such as amitriptyline and its active metabolite nortriptyline would be metabolised 
successfully, or perhaps, at a slightly decreased rate. However, in this case, this would simply 
be an assumption, without knowledge of all the contributing factors, including the dose, the 
unknown significance of genetic variants observed and the functionality of CYP2C19 
metabolism. 
If it were to be found that there were toxic levels of amitriptyline and/or nortriptyline in the 
blood of the deceased and that the deceased had reportedly taken a therapeutic dose of the drug, 
then the presence of both may be associated with a deficient CYP2D6 activity, which is often 
observed in an IM phenotype (Smith and Curry, 2011). This may have contributed to a 
prolonged elevation in antidepressant levels in the deceased, as a result of the inability to clear 
the drug efficiently (Smith and Curry, 2011). For this to be said with more confidence the 
metabolic function of CYP2C19 would have to be investigated. A similar mechanism is 
described in a case report investigated by Smith and Curry (2011), whereby an individual who 
was suspected to have ingested 99 tablets of 25 mg amitriptyline, had experienced a delayed 
rise in serum TCA levels and prolonged intoxication as a result of CYP2D6 deficiency (Smith 
and Curry, 2011).  
Dalén et al. (1998) performed a study in which a dose of nortriptyline was administered to 
several individuals with varying numbers of active CYP2D6 alleles. As expected, the 
individuals with inactive alleles possessed the highest concentration of nortriptyline; 
suggesting that a deficient enzyme activity contributes to high levels of nortriptyline (Dalén et 
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al., 1998). While it is debatable whether it is worthwhile performing genetic analyses on 
polymorphic CYP450s in suspected amitriptyline overdoses, forensic toxicogenetics may 
prove constructive in cases where case and drug use history speaks against suicidal intent or 
where medical-related deaths may have arisen from adverse drug reactions (Koski et al., 2006). 
These findings warrant a quantitative toxicological investigation into amitriptyline to 
distinguish whether there may have been any contribution to death. Given that amitriptyline 
toxicity has been purported to be associated with myocardial infarction as a result of 
myocardial cell damage (Kiyan et al., 2006), the genetic results here may assist in 
distinguishing contributors to death. In this regard, an individual with a decreased CYP2D6 
activity, which results in amitriptyline toxicity, may experience abnormal cardiac function 
(Kiyan et al., 2006). However, the current study was not able to determine whether the case in 
question was that of amitriptyline toxicity, therefore, such an association cannot be made here. 
Although, further investigation into cases with similar circumstances should be pursued. 
4.2 Case 2 
 
4.2.1 Case History 
 
A 25-year-old Coloured male was found by his mother, unresponsive with creamy white 
vomitus on his anterior chest and neck area. According to his mother, he had been complaining 
of headaches for months. The deceased was a known schizophrenic on prescribed medication. 
He received a set monthly injection, and depending on his wellbeing received additional 
prescribed medication. His mother claimed that he may have gotten hold of hidden medication. 
A post-mortem was performed and the following findings were deduced: (i) Low-dose full-
body X-ray (LODOX) showed an enlarged heart with widened mediastinum, straightened left 
border of heart and bilateral lung infiltrates especially on the right; (ii) Vomitus on anterior 
chest and neck area; (iii) Brain was swollen and oedematous and (iv) Arteries of the heart 
showed arteriosclerotic occlusion. As a result, it was concluded by the forensic pathologist that 
the cause of death was associated with acute cardiac disease.  
Considering the possibility of contributory intoxication given the history, following next-of-
kin consent, blood was taken for DNA analysis and toxicological screening. The following 
drugs were detected: fluoxetine, ephedrine, doxylamine and diphenhydramine (Table 6 and 
Appendix 6). Following a genetic analysis, genetics variants observed in the deceased suggest 
that he was an IM. 
 
 





4.2.2 Relationship between an Identified Drug and the Predicted Phenotype 
 
CYP2D6 is reported to play a role in the metabolism of the detected drugs fluoxetine and 
diphenhydramine. Fluoxetine is one of the most widely used selective serotonin reuptake 
inhibitor (SSRI) antidepressant prescribed drugs, for several different psychopathological 
disorders (Llerena et al., 2004). Fluoxetine has been the focus of many CYP450 enzyme-
related studies because of the role CYP2D6 plays in the metabolism of the compound, and 
because of its known potent inhibitory properties of the enzyme (Llerena et al., 2004) (Figure 
13). This emphasises the difficulty in assessing the contribution of a drug towards the death of 
an individual (Llerena et al., 2004). 
Plasma drug concentrations of fluoxetine and its metabolites norfluoxetine have shown to be 
affected by the genetic variations in CYP2D6 and therefore the efficacy of the drug is ultimately 
effected (Charlier et al., 2003). A study performed by Charlier et al. (2003), suggested that 
genotyping of CYP2D6 in addition to therapeutic drug monitoring to explain side effects is the 
way forward. However, in a forensic context, the investigation should include comprehensive 
toxicological analyses and ideally a genetic analysis to determine metabolic phenotype in 
addition to quantitative data. 
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From the variants identified after applying the fully optimised assay to case 2, the deceased 
was found to have possessed the following haplotypes: CYP2D6*13, *17, *1D, *27, *43 and 
*86. Although, the haplotype *13 plays a significant role in the prediction of the phenotype in 
this case, it is the contribution of another haplotype *17 that reinforces the prediction. The 
presence of four variants namely; c.320C>T, c.408G>C, c.886C>T and c.1457G>C contribute 
to the formation of the CYP2D6*17 haplotype (Masimirembwa et al., 1996).  
CYP2D6*17 has been thoroughly researched and is known to give rise to substrate-dependent 
decreased activity (Ingelman-Sundberg, 2005; Zhou, 2009). While the *17 haplotype is 
virtually absent in Caucasians it occurs at a relatively high frequency in African populations 
(Zhou, 2009). Table 1 in the literature review shows the frequency of *17 in several different 
African populations, with the highest being that of the Zimbabwean population (34%) (Dandara 
et al., 2001; Bertilsson et al., 2001). The CYP2D6*17 haplotype is one of two alleles specific 
to African populations associated with an IM phenotype and remains one of the most important 
functional alleles in the metabolism of CYP2D6 substrate drugs (Alessandrini et al., 2001; 
Matimba et al., 2008).  
While CYP2D6*13 renders one allele inactive in this case, the homozygous CYP2D6*17 was 
found on both alleles and is also associated with an altered functionality. With both alleles 
exhibiting decreased function, this individual was classified as an IM. This was the most likely 
interpretation, but it must be noted that SNPs were found, with unknown significance, and 
therefore, this interpretation may be different when we learn more about the other SNPs.   
In this case, the predicted phenotype was identified as an IM; however, with regards to the 
presence of fluoxetine, its inhibitory properties on CYP2D6 activity has the ability to make an 
IM phenotype resemble a PM phenotypes, a phenomenon known as phenocopying (Hemeryck 
and Belpaire, 2002; Torkamani, 2016). The inhibitory properties of fluoxetine are, according 
to Kirchheiner et al. (2004), a result of multiple doses, which contribute to the decrease in 
CYP2D6-mediated metabolism (Kirchheiner et al., 2004).  The ability of fluoxetine and other 
SSRIs to inhibit their own metabolism, producing increased plasma concentration levels of the 
drug, constantly highlights the difficulty of assessing the effect of altered CYP2D6 metabolism 
on itself. However, the presence of alleles such as *17, found in African populations, that lead 
to diminished function are very frequent and may, particularly when present in a homozygous 
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If a quantitative toxicology analysis was performed on the blood samples retrieved in this case 
and an inconsistent level of fluoxetine was revealed, the reduced enzyme activity, as a result 
of *13/*17, and the constant inhibition of the CYP2D6 enzyme could potentially be the 
contributing factors (Llerena et al., 2004). Since the discovery of the inhibitory properties of 
SSRIs, it has been noted that when administering other substances, metabolised by CYP2D6, 
in combination, as seen in this case, caution must be taken (Torkamani, 2016). For example, 
administering an SSRI such as fluoxetine together with a TCA, would create an antagonistic 
environment and would make an interpretation complex (Llerena et al., 2004). A significant 
limitation would be not being able to determine the effect of drug-drug interactions and the 
interaction with the metabolising enzyme.  
4.2.3 Interpretive Challengers    
Apart from the drugs reported in the two cases, the polymorphic CYP2D6 gene is also known 
for its ability to metabolise drugs from certain illicit drug groups, namely: amphetamine-type 
stimulants, opioid analgesics and sedative hypnotics (Kupiec et al., 2006; Crews et al., 2012; 
Koski et al., 2007; Neukamm et al., 2013; Jannetto et al., 2002; Druid et al.,1999). CYP2D6-
mediated metabolism of these drugs is known to be a major source of variation, both in drug 
effect and pharmacokinetics (Jamei et al., 2009). This makes the interpretation of the results 
challenging when considering most of the reported substances in case 1 and 2 were not 
metabolised by CYP2D6, alone. This warrants the development and optimisation of multiple 
CYP450 assays. As even if an individual were to produce an inactive variant for an enzyme in 
the major metabolic pathway, the drug may be broken down through an alternate route, 
assuming all necessary enzymes, are not genetically altered (Wu, 2011). Conversely, 
individuals may simultaneously possess several reduced function alleles for multiple CYP450 
gene, therefore, exhibiting significant variances in toxicological effects of the drug (Wu, 2011).    
Drug-drug interactions also contribute to interpretive challenges according to Hyland et al. 
(2001), who proposed that clinicians should always be aware of the possible drug-drug 
interactions when prescribing drugs metabolised by CYP450 enzymes, in conjunction with 
known inhibitors of the enzymes (Hyland et al., 2001). In both cases, several drugs that are 
metabolised by more than one CYP450 enzyme and are inhibitors of CYP450 enzymes, were 
reported. For instance, in case 1 Citalopram was reported in the drug screen and is known to 
be metabolised mostly by CYP2C19, but also by CYP3A4 and CYP2D6 as well (Herrlin et al., 
2003). Knowledge of the function each enzyme is responsible for is considered a prerequisite 
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for predicting variable pharmacokinetics and drug response (Zanger and Schwab, 2013). This 
allows for further interpretation of possible drug-drug interactions. 
4.3 Strengths and Limitations 
 
4.3.1 Post-mortem Toxicogenetics 
 
Even with the substantial improvement in our understanding of the significance, together with 
vast advances in the application of forensic toxicology, interpretation of post-mortem forensic 
toxicological results remains a challenge in its own regard (Drummer, 2004; Musshoff et al., 
2010). Given the difficulties of interpretation, a full picture of the circumstances surrounding 
the case needs to be considered (Drummer, 2004).  
In a traditional drug testing scheme, two different tiers of testing are employed; a qualitative 
and quantitative test (Milone, 2012). The first tier comprises of a qualitative presumptive test 
often in the form of a drug screen, which is used to detect and identify drugs in the blood 
(Milone, 2012). A quantitative confirmatory test, therefore, forms part of the second tier, which 
is performed in order to quantify the drugs reported in the initial screen.  
In both case 1 and 2, no quantitative analysis was performed. No quantitative analyses were 
performed as there are currently no relevant standards, in a forensic toxicology context, 
available in South Africa for the drugs detected. The lack of quantitative toxicological results 
and case history rendered the interpretation of the drugs reported difficult. The high case load 
experienced at SRM, often results in only selected cases being sent for toxicological screening, 
with quantitative drug analyses not being routinely performed. 
Essentially the suggested metabolic effects of the phenotypes on the presence of the reported 
drugs, were merely hypothetical. In addition, determining the exact mechanism of metabolism, 
becomes an even more difficult task when there is either; (i) a combination of CYP450 enzymes 
that contribute to the metabolism of drugs present in the blood; (ii) several drugs reported that 
are metabolised by the same CYP450 enzymes or (iii) the presence of drugs that are known to 
be metabolised as well as inhibited by CYP450 enzymes.  
The value of a quantitative analysis is imperative, when keeping in mind that CYP2D6 is also 
prone to inhibition by numerous drugs, as seen in case 2 where fluoxetine was reported (Zanger 
and Schwab, 2013). The phenomenon known as phenocopying, as previously mentioned, is 
when an inhibitor is strong enough to change the apparent phenotype of the individual (Zanger 
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and Schwab, 2013). The inhibition of drug metabolism often results in undesirable elevated 
plasma drug concentrations of other drugs metabolised by the same enzyme (Hemeryck and 
Belpaire, 2002). This could be observed in such a case as case 2, whereby the inhibitory effects 
of fluoxetine, could lead to a decreased metabolism of diphenhydramine, causing an increase 
in the plasma drug concentration. The importance of the identification of the major CYP450 
enzymes involved in the metabolism of a potential drug is paramount in contributing to future 
predictions for potential drug-drug interactions, which could ultimately help resolve 
ambiguous cases (Bohets et al., 2000; Hemeryck and Belpaire, 2002).  
A co-segregation analysis is used to test the mode of inheritance of a particular genotype 
(Elston, 1981) and would provide insight into which alleles the different variants were situated 
on. (Jarvik, 1998). A second limitation was that parents of the deceased were unavailable for 
the study, which prevented the performing of co-segregation analysis. Without being able to 
perform a co-segregation analysis, there was an inability to determine the true metabolic 
phenotype in case 1, based on the alleles that were identified. Not performing co-segregation 
analysis does not always limit the prediction of a phenotype, as seen in case 2; whereby the 
homozygosity of variants meant that both alleles had decreased enzyme activity.  
Apart from the identified limitations, this assay still needs to be thoroughly researched and 
validated, before it can be utilised in service.  
4.3.2 A Population with Limited Population Frequency Data 
 
During this study, it transpired that there was a paucity of related studies in an African and 
South African context. This was highlighted during the optimisation phase of this study, 
whereby a primer set had to be amended as a result of the lack of frequency data on a variant, 
specifically the c.180+52_180+53delGAinsCC variant. This can be attributed to most 
pharmacogenetic studies to date have been conducted on a limited number of population 
groups, namely: Caucasian, Oriental and African American populations (Ikediobi et al., 2011). 
A study by Koboldt et al. (2006), illustrated how a primer-site variant, such as a SNP, could 
conceivably have a very rare minor allele frequency and have no effect on the hybridisation of 
primers, therefore, essentially having no effect on the ability of the primer to contribute to 
amplification of the target region (Koboldt et al., 2006). However, the variants observed in the 
primer binding region in this study clearly effected the hybridisation of the primer (5’-
CCCTACCAGAAGCAAACA-3’) designed by Matimba et al. (2009), used in this study, to 
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the target region.  
The pharmacogenetic data categorised in these populations are often extrapolated for the use 
of inferring information in other populations, despite this introducing numerous problems 
(Ikediobi et al., 2011). One such problem is the presence of variants, found to have a high 
frequency in a Caucasian population, are actually very rare in other populations and vice versa 
(Ikediobi et al., 2011). One such case is that of the CYP2D6*17 haplotype, which is common 
in African populations but rarely found in others (Dandara et al., 2001). It is important to 
appreciate that there are large inter-ethnic differences for CYP2D6 polymorphisms and their 
resulting metabolic phenotypes (Allorge and Tournel, 2011; Dandara et al., 2001). African 
populations are known to be among the most genetically diverse in the world, which highlights 
the importance that assumptions should not be made for such African populations based on 
phenotypic predictions from other similar studies and that there is a void of information for 
these unique African populations (Gaedigk and Coetsee, 2008; Ikediobi et al., 2011).  
In South Africa, where CYP2D6 allele frequency data are sparse and only, recently emerging 
for geographically defined or indigenous populations, admixed populations, in particular the 
mixed ancestry ‘Coloured’ population, should be targeted in order to fill that void (Gaedigk 
and Coetsee, 2008). Unless an extensive genotyping study is performed, many less frequent, 
rare SNPs, will go unnoticed, avoiding detection and in turn frequencies of default alleles will 
be overestimated (Gaedigk et al.,2017). Teh and Bertilsson (2012), illustrate how there are 
marked differences in CYP2D6 genotypes and phenotypes in populations of different racial 
origins, whereby certain alleles are found in high frequency in Oriental populations that are 




By drawing on similar studies within the literature, a fully optimised molecular-based assay, 
which was able to amplify and sequence all the exons within the CYP2D6 gene, was 
designed. The assay has been optimised from a technical perspective but testing it in a larger 
cohort would be needed to verify its success rate for sequencing in a larger cohort. A 
challenge that arose during optimisation, included amending the original nine primer sets to 
eight, however, this proved to be a minor issue and was successfully dealt with.   
To demonstrate a proof of concept, the assay was successfully applied to DNA from two 
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decedents admitted to Salt River Mortuary and the results were also analysed and interpreted, 
in context of limited toxicological data. The analysis of the two cases rendered the decedents 
as (i) either an IM or EM, and (ii) IM respectively. The two chosen cases were initially 
suspected to have had drugs contribute to death, thus a toxicological screening was performed. 
Taking into consideration that no quantitative analysis was performed, only a hypothetical 
reasoning behind the drugs reported in the screening, could be given. Even without a 
quantitative analysis, knowledge regarding polymorphic CYP450s involved in drug 
metabolism will help anticipate certain observations or guide further investigations.   
The genetic variants that contributed to the predicted phenotypes, combined with the presence 
of the drugs identified in each case, suggests altered drug metabolism could have occurred, 
which should be investigated further and interpreted within each case context. The findings in 
this study would be beneficial, not only into resolving ambiguous cases, but also to the 
decedents’ living relatives, who may also carry these variants. Testing for CYP2D6 variants in 
the living relatives would identify those at risk for such adverse drug reactions. Overall, this 
study demonstrates the value of molecular analyses in forensic investigations of toxicological-
related fatalities, and lays the foundation for additional future research, particularly since the 
molecular assay has now been successfully optimised. 
The knowledge of South Africa having distinctly diverse populations has made it clear how 
personalised medicine in a country like South Africa faces many challenges. This largely 
influences how medical professionals, especially pathologists, are able to analyse and interpret 
results in toxicological-related deaths. Without a molecular component as a part of routine 
forensic autopsies, many cases may remain unanswered even after a thorough investigation. It 
is evident how a genetic analysis attests to its value and could prove instrumental in 
contributing to a large number of ‘would be unresolved’ cases actually being successfully 
resolved. Although, results from a genetic analysis may not always be noteworthy they may 
always serve as a helpful complement to already identified alterations.  
In the little research that has been performed on unique admixed populations in South Africa, 
the data presented has demonstrated the importance of characterising such populations, in 
respect to the complement of CYP2D6 alleles present and their frequencies. It is evident that 
without an extensive genotyping study being performed, many novel variations, that could 
ultimately contribute to certain haplotypes, will go unnoticed. Therefore, variations avoiding 
detection, will result in frequencies of default alleles being overestimated. Without this 
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knowledge and ultimately the knowledge of the frequencies of the metabolic phenotypes in a 
local context, one would realise how much still goes undiscovered in routine forensic 
investigations. It is paramount that forensic pathologists and toxicologists are aware of the 
biological influences and their possible side effects as this would possibly contribute to the 
determining a cause and/or manner of death. 
Toxicogenetics has been advocated as an important compliment to the investigation of death 
and if appropriately implemented and utilised in conjunction with routine post-mortem 
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Appendix 2  




Study title: Exploring Genetic Variation in Drug Metabolising Enzymes in Drug Intoxication 
Cases at Salt River Mortuary 
Researcher: Devin Vincent (VNCDEV001) 
Supervisor: Laura Heathfield 
Co-Supervisor: Bronwen Davies 
 
Introduction to the study 
You are invited to participate in a research study that will take place within the Division of 
Forensic Medicine and Toxicology at the University of Cape Town. It will be conducted by 
Devin Vincent who is a researcher in the Division of Forensic Medicine and Toxicology at the 
University of Cape Town, working towards his Master’s degree in Biomedical Forensic 
Science. 
 
The purpose of the forensic toxicogenetic research study is to explore the genetic variation in 
drug metabolising enzymes in drug intoxication fatalities by examining the presence of 
predispositions in CYP450 gene expression and function. This form explains what is expected 
of you if you choose to participate in this study. It is important that all information is read 




The South African pathology services are often faced with cases in which scene, autopsy and 
toxicological evidence are all consistent with an overdose and fatal toxicity, however, 
sometimes the toxicological data in some cases is ambiguous and conclusions concerning the 
cause and manner of death are limited in scientific validity. In such instances, death may have 
been caused by issues in drug metabolism – the process by which human bodies process drugs 
introduced into the body. A test that could be performed to investigate the occurrence of such 
an event is one that examines the sequence of the specific CYP450 genes that are responsible 
for the metabolism of the implicated drug to determine if the decedent is not genetically 
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predisposed to experience toxicity from the drug even when taken at a therapeutic level. 
Currently there are no validated molecular-based assays designed for identifying ineffective or 
genetically altered CYP450 genes. This makes it difficult to understand the influence genetic 
polymorphisms have on CYP450 expression and functionality. 
 
However, to be able to design a validated molecular-based assay that could be incorporated 
into the routine tests done by forensic pathologists, biological samples such as blood needs to 
be collected from individuals and the DNA extracted and analyzed in order to help with 
optimization. The optimized assay will help forensic pathologists in their postmortem 
examinations, which will in turn facilitate and increase the accuracy by which they determine 
the manner and cause of death.  
 
Procedure  
You will be asked to give permission to allow for blood to be collected by a registered 
doctor/nurse using an invasive blood collection technique: 
 
• 4 – 5 ml of blood will be collected in a purple top tube, which is done using an invasive 
method which incorporates the use of sterilised needles and blood collection vials. 
 
Once samples are collected, there will be laboratory tests on the samples to extract the DNA, 
study the DNA more closely and use the DNA to design molecular-based assays. Please note 
that technology in the laboratories are always getting better so in time there might be newer 
laboratory techniques invented that may become accessible to the researcher.  You will also be 
asked to allow the biological samples collected to be used in these newer technologically 
advanced methods if and when they become available.   
 
The biological material collected and the extracted DNA will be stored for a period of 20 years 
at the Division of Forensic Medicine (authorised institution) at the University of Cape Town. 
After this time the samples will be appropriately discarded. 
 
Each participant’s name will not be made known. Instead the samples, extracted DNA and 
generated data will be coded which means that any identifiers will be replaced with numbers 
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1. Every person involved in the project will be required to fill in a confidentiality 
agreement. 
2. Only the primary researcher (Devin Vincent) will have access to the database. 
3. All samples, genetic data and results generated will be stored in locked filing cabinets 
and password protected files in the Division of Forensic Medicine at the University of 
Cape Town. 
4. Sharing of experimental data will be done on the basis of alphabetical and numerical 
codes.   
5. The results of the study may be published or presented at meetings but the identity of 
the participant will not be revealed. 
6. Your participation will be kept confidential. 
 
The biological samples will not be used for any research unless the research study is reviewed 
and approved by the University of Cape Town, Faculty of Health Sciences, Human Research 
Ethics Committee. This committee is responsible for protecting the rights and welfare of 
individuals who volunteer for participation in research studies.   
 
Several things that you need to know before providing biological samples: 
 
1. When research is carried out it is not the policy of the University of Cape Town to 
provide genetic information uncovered about the participant.  
2. Participation in this study is completely voluntary. You are free to not participate or to 
withdraw at any time, for whatever reason, without negative consequences. In such 
cases no samples will be collected and your choice will not affect the way you will be 
treated at the Division of Forensic Medicine and Toxicology. 
3.  If you participate in the study, and you wish to not participate any longer and you do 
not want the biological sample to be used in this study. Please let us know and we will 
destroy the samples, immediately. If the sample has already been analysed at the time 
you change your mind, your results and other data may have already been shared with 
other researchers. In that case, we will not be able to destroy this data. The data will, 
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however, be removed from the secured database. That means that no additional/future 
researchers can get the data.  
4. You will not receive feedback of possible genetic variations that are found in the DNA. 
This study is unlikely to benefit you directly, but it is hoped that it will contribute to 
knowledge about the presence of predispositions in CYP450 gene expression and 
function with regards to drug intoxication fatalities in the future.  
5. There will be no cost to you and there will be no compensation for your participation. 
Making your choice 
Please read each sentence below and think about your choice. After reading each sentence; 
please tick the Yes or No box.  No matter what you decide, it will not negatively affect you in 
any way. 
 
If you may have any questions please don’t hesitate to ask the person taking the consent. If you 
may have any questions with regards to the rights and welfare of a research subject in the study, 
please contact the Chairperson of the University Of Cape Town Faculty Of Health Science 
Human Research Ethics Committee, Professor Marc Blockman on (021) 406 6496. If you 
require any further information about this study please contact Devin Vincent at 082 496 7301 
or email at VNCDEV001@myuct.ac.za 
 
If the volunteer agrees then the consent form needs to be read and informed consent will be 
taken. 
- Thank you for your time - 


















I, _______________________________________________________________ (full name), 
hereby acknowledge my participation in the research study following the completion of this 
form.  
1. I confirm that I have: Yes No 
a) Read and understood contents of this form and agree to be a part of the 
research study. 
  




2. I give consent and agree that: Yes No 
a) Biological samples in the form of blood can be taken and subjected to 
laboratory tests at the Division of Forensic Medicine and Toxicology in 
which DNA will be extracted and analysed to better understand genetic 
predispositions in CYP450 gene expression and function. 
  
b) Agree that the DNA extracted from the sample may be stored in the Division 
of Forensic Medicine at the University of Cape Town for a period of 20 
years after which it will be appropriately discarded. 
  
c) The stored genetic material may only be used further research studies which 
have been reviewed and approved by the University of Cape Town, Faculty 
of Health Sciences, Human Research Ethics Committee.  
  
   
3. I further understand that: Yes No 
a) The treatment and management of the biological samples will be in 
accordance with guidelines of the University Of Cape Town Faculty Of 
Health Science Human Research Ethics Committee. 
  
b) The genetic laboratory is under obligation to respect medical 
confidentiality. 
  
c) This study is unlikely to benefit me directly.   
Study Case no.______________ 
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d) I can at any time withdraw my consent and that I have to notify the primary 
researcher of my decision to withdraw. 
  
e) I may be contacted in the future by someone from the University of Cape 
Town who may ask me to take part in research that may or may not be 
directly linked to the proposed study. 
  
   
I, have explained to _________________________________________________(full name);  
the purpose, procedures, possible benefits and discomfort of this research study; and how the 
samples will be collected and stored in the Division of Forensic Medicine and Toxicology at 
the University of Cape Town for use in the study and in possible further research by other 
individuals within the Forensic Medicine at the University of Cape Town.  
   
Full name of person obtaining consent     
  
Signature of person obtaining consent    Date      
   
Full name of person authorising consent for  
collection of samples for use in research study 
   
Signature of person authorising consent for                                          Date 
collection of samples for use in research study 
 
Full name of witness      
              
Signature of witness          Date                                                
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PARTICIPANT QUESTIONNAIRE  
 
Participant reference number:  _____________ 
 
1. Sex         Male              Female 
 
2.  Age        18 – 29         30 – 50          50+ 
 
3.  Self-reported population group according to South African Census categories 
 
 African Black      Coloured       Indian/Asian       White    
 
4.   Ancestral origin (if known)  
      European  
     Africa  
     Asian  
      Middle Eastern  
      Other     
           Specify: ______________________________ 
 
7. Your self-reported ethnicity (With reference to cultural self-identification) 
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Appendix 3  




Study title: Postmortem Toxicogenetics: determining the suitability of blood samples collected 
for routine toxicological analyses for use in subsequent genetic analyses. 
Principal investigator: Loyiso Vuko 
Supervisor: Ms. Bronwen Davies 
Co-supervisors: Ms. Laura Heathfield 
      Ms. Katrina Auckloo 
 
Introduction to the study 
You are invited to participate in a research study under University of Cape Town’s Division of 
Forensic Medicine and Toxicology, in the Department of Pathology. 
 
It will be conducted by Loyiso Vuko, who is a researcher in the division, and a candidate for 
an M.Phil degree in Biomedical Forensic Science.  
 
The purpose of this study is to determine whether blood – a biological sample that is routinely 
collected at autopsy for toxicological analyses (tests that investigate the presence and amount 
of drugs/chemicals in the body of the deceased) – can be used for a genetic analysis following 
toxicological analysis. This form explains what you will be asked to do if you decide to 
participate in this study. Please read it carefully and feel free to ask any questions you may 
have before you make a decision about participating. 
 
Background 
Determining the cause and manner of death at autopsy is one of the core functions of forensic 
pathology services. This is performed by conducting an anatomical autopsy and incorporating 
all the evidence that is at the disposal of the responsible Forensic Pathologist. This exercise is 
not always straightforward in cases of drug-related deaths and those in which the decedent died 
in a sudden and unexpected manner. This is because while there are cases in which scene, 
autopsy and toxicological evidence are all consistent with an overdose and fatal toxicity, South 
African forensic services are often faced with cases in which the toxicological data is 
ambiguous and conclusions concerning the cause and manner of death are limited in scientific 
validity. In such instances, death may have been caused by issues in drug metabolism – the 
process by which human bodies process drugs introduced into the body.  
 
The current postmortem procedure in South Africa does not involve a test by which such 
phenomenon could be investigated. One test that could be performed to investigate the 
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occurrence of such an event is one that examines the sequence of the specific genes that are 
responsible for the metabolism of the implicated drug to determine if the decedent is not 
genetically predisposed to experience toxicity from the drug even when taken at a therapeutic 
level. 
 
However, in order for such a test to be incorporated into the routine work of forensic pathology, 
it should be determined whether the blood that will be used – collected at autopsy by the 
Forensic Pathologist for toxicological analysis – will have Deoxyribonucleic acid (DNA – 
genetic material) of sufficient quality to perform the test after it (the blood sample) has 
undergone the process of toxicological analyses. This is what this study aims to investigate. 
Information gathered from this study will help the practitioners in postmortem investigation to 
make an informed decision on whether to use blood samples that are routinely used for 
toxicological investigations or to collect separate blood samples for the aforementioned genetic 
analysis, which will in turn facilitate and increase the accuracy by which Forensic Pathologists 
pronounce on the cause and manner of death. 
 
Procedure 
You will be asked to give permission to allow for blood to be collected at autopsy by the 
Forensic Pathologist assigned the case for your deceased family member. The samples will be 
collected into three different types of collection tubes, two of which are routinely used to collect 
blood at autopsy for toxicological analysis, while the other one is custom-made to preserve 
DNA for the purpose of making comparisons with the former. 
 
Some of these samples will undergo toxicological analysis as is routinely performed in 
postmortem investigations, following which the DNA will be extracted in preparation for the 
determination of the quality of the DNA in those blood samples by means of laboratory tests 
that include spectrophotometry, quantitative Polymerase Chain Reaction and DNA Profiling. 
These samples will be compared to those that had undergone toxicological analyses. Please 
note that technologies in the laboratories are constantly being improved, and that it is possible 
that by the time the samples get processed in this study the laboratory may have upgraded to 
newer and more advanced technologies. You will also be asked to allow for the samples to be 
processed using these advanced technologies in the event of such an upgrade occurring. 
 
The biological material collected from your deceased family member and the extracted DNA 
will be stored for a period of 20 years at the Division of Forensic Medicine and Toxicology 
(authorised institution) at the University of Cape Town. After this time the samples will be 
appropriately discarded. 
 
The name and every other personal detail of your family member will not be made known. 
Each case will be given a unique identification code to maintain the anonymity of the deceased. 
These identification codes will be used to trace the collected samples throughout the course of 





- 69 - 
7. Every person involved in the project will be required to fill in a confidentiality 
agreement. 
8. Only the primary investigator will have access to the database. 
9. All samples, genetic data and results generated will be stored in locked filing cabinets 
and password protected program in the Division of Forensic Medicine and Toxicology 
at the University of Cape Town. 
10. Sharing of experimental data will be done on the basis of the unique identification 
codes.   
11. The results of the study may be published or presented at meetings but the identity of 
the deceased and the family will not be revealed. 
12. Your participation will be kept confidential. 
 
The biological samples will not be used for any research unless the research study is reviewed 
and approved by the University of Cape Town, Faculty of Health Sciences, Human Research 
Ethics Committee. This committee is responsible for protecting the rights and welfare of 
individuals who volunteer for participation in research studies.   
 
There are several things you need to know before allowing biological samples to be taken 
from your deceased family member: 
6. When research is carried out, it is not the policy of the University of Cape Town to 
provide genetic information about the deceased to the family members.  
7. Participation in this study is voluntary. You are free not to participate or to withdraw at 
any time, for whatever reason, without negative consequences. In such cases, no 
samples will be collected and your choice will not affect the way you will be treated at 
the Salt River Mortuary. 
8.  If you participate in the study, you can change your mind later and decide that you 
don’t want to participate anymore and you do not want the tissue to be used in this 
study. Please let us know and we will destroy the samples. If the sample has already 
been analysed at the time you change your mind, your results and other data may have 
already been shared with other investigators. In that case, we will not be able to destroy 
this data. The data will be removed from the secured database. That means that no 
additional researchers can get the data.  
9. You will not receive feedback of possible genetic variations that are found in the DNA 
of the deceased. This study is unlikely to benefit you or your family directly, but it is 
hoped that it will contribute to knowledge about the influence of genes in drug-toxicity 
in the future. 
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Making your choice 
Please read each sentence below and think about your choice. After reading each sentence, 
please tick the Yes or No box.  No matter what you decide, it will not negatively affect you or 
your deceased family member in any way. 
 
If you may have any questions or require referral to a grief centre or psychological support, 
please don’t hesitate to ask the person taking the consent. If you may have any questions with 
regards to the rights and welfare of a research subject in the study, please contact the 
Chairperson of the University Of Cape Town Faculty Of Health Science Human Research 
Ethics Committee, Professor Marc Blockman on (021) 406 6496. If you require any further 
information about this study, please contact Loyiso Vuko at 083 538 4283 or email at 
VKXLOY001@myuct.ac.za 
 
If the spouse/partner/major child/parent/guardian/major sibling agrees then the consent form 
needs to be read and informed consent will be taken. Please note that the information and 
consent forms will be translated into the family member’s language of choice.  
- Thank you for your time - 
Please find attached the consent form to be signed if you wish to proceed
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CONSENT FORM 
I, _______________________________________________________________ (full name), 
the spouse/partner/major child/parent/guardian/major brother/major sister (circle relationship) 
of the deceased; fill in the Western Cape death register number: WC11 
I confirm that I have: Yes No 
c) Read and understood contents of this form and agree to be a part of the research 
study. 
  
d) Been informed about this study’s purpose, procedures, possible benefits, and risks.   
 
I give consent and agree that: Yes No 
d) Blood sample(s) can be taken from my deceased family member.   
e) The blood sample(s) can be subjected to laboratory tests at the Division of Forensic 
Medicine and Toxicology in which DNA will be extracted and its quality assessed 
after toxicological analysis.  
  
f) Agree that the samples and extracted DNA may be stored in the Division of 
Forensic Medicine and Toxicology for a period of 20 years after which it will be 
appropriately discarded. 
  
g) The stored genetic material may only be used for further research studies which 
have been reviewed and approved by the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee.  
  
h) I may be contacted in the future by someone from the University of Cape Town 
who may ask me to take part in research that may develop from the results of the 
study. 
  
   
I further understand that: Yes No 
f) The treatment and management of the biological samples of my deceased family 
member will be in accordance with the guidelines of the University Of Cape Town 
Faculty Of Health Science Human Research Ethics Committee. 
  
g) The forensic laboratory is under obligation to respect medical confidentiality.   
h) This study is unlikely to benefit me or my family directly.   
i) I can, at any time, withdraw my consent and that I have to notify the primary 
investigator of my decision to withdraw. 
  
j) Research conducted with this DNA may result in publication, but neither the 
deceased nor the family of the deceased will be identified.  
  
 
I, have explained to _________________________________________________(full name) 
who is the spouse/partner/major child/parent/guardian/major brother/major sister of the 
deceased;  the purpose, procedures, possible benefits and discomfort of this research study; and 
how the samples will be collected and stored in the Division of Forensic Medicine and 
Toxicology at the University of Cape Town for use in the study and in possible further research 
by other individuals within the Division of Forensic Medicine and Toxicology at the University 
of Cape Town.  
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Full name of person obtaining consenting     
   
Signature of person obtaining consenting    Date      
   
Full name of person authorising consent for  
collection of samples at autopsy for use in research study 
   
Signature of person authorising consent for                                          Date 
collection of samples at autopsy for use in research study 
Thumb print of the spouse/partner/major child/parent/guardian/major brother/major sister of 
the deceased:                              






Full name of witness      
              






















Figure A: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 











Figure B: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 









     MWM    NTC   50.0°C   51.0°C  52.7°C   55.3°C  58.5°C  61.2°C 
	






















Figure C: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 











Figure D: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 
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  MWM      NTC     50.0°C   51.0°C   52.9°C    55.7°C  59.1°C   62.0°C    63.8°C   65.0°C 
	













Figure E: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 












Figure F: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 



























Figure C: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 











Figure D: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature gradient 
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     MWM      NTC      52.0°C    53.5°C    58.4°C    60.0°  
	
Figure G: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 













Figure H: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 




























Figure I: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 
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Figure G: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 













Figure H: A 1% agarose gel run for 80 minutes at 100 volts representing a temperature 
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Figure A: A 1% agarose gel run for 80 minutes at 100 volts, representing amplification of 
exon 1 part 1 and 3 in the four different controls and case 1. MWM: 50bp molecular weight 
marker; NTC: No Template Control; 1: Control 1; 2: Control 2; 3: Control 3; 4: Control 4 










Figure B: A 1% agarose gel run for 80 minutes at 100 volts representing amplification of exon 
2/3 and 4 in the four different controls and case 1. MWM: 50bp molecular weight marker; 


















Figure C: A 1% agarose gel run for 80 minutes at 100 volts representing amplification of exon 
5/6 and 7 in the four different controls and case 1. MWM: 50bp molecular weight marker; 




Figure D: A 1% agarose gel run for 80 minutes at 100 volts representing amplification of exon 
8 in the four different controls and case 1. MWM: 50bp molecular weight marker; NTC: No 



















Figure E: A 1% agarose gel run for 80 minutes at 100v representing amplification of exon 9 
in the four different controls and case 1. MWM: 50bp molecular weight marker; NTC: No 
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Case 2 
